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Introduction Commercial treatment planning systems employ a variety of dose calculation 
algorithms to plan and predict the dose distributions a patient receives during external beam 
radiation therapy.  Traditionally, the Radiological Physics Center has relied on measurements to 
assure that institutions participating in the National Cancer Institute sponsored clinical trials 
administer radiation in doses that are clinically comparable to those of other participating 
institutions.  To complement the effort of the RPC, an independent dose calculation tool needs 
to be developed that will enable a generic method to determine patient dose distributions in 
three dimensions and to perform retrospective analysis of radiation delivered to patients who 
enrolled in past clinical trials.  
Methods A multi-source model representing output for Varian 6 MV and 10 MV photon beams 
was developed and evaluated.  The Monte Carlo algorithm, know as the Dose Planning Method 
(DPM), was used to perform the dose calculations.  The dose calculations were compared to 
measurements made in a water phantom and in anthropomorphic phantoms.  Intensity 
modulated radiation therapy and stereotactic body radiation therapy techniques were used with 
the anthropomorphic phantoms.  Finally, past patient treatment plans were selected and 
recalculated using DPM and contrasted against a commercial dose calculation algorithm.  
Results The multi-source model was validated for the Varian 6 MV and 10 MV photon beams.  
The benchmark evaluations demonstrated the ability of the model to accurately calculate dose 
for the Varian 6 MV and the Varian 10 MV source models.  The patient calculations proved 
that the model was reproducible in determining dose under similar conditions described by the 
benchmark tests.   
Conclusions The dose calculation tool that relied on a multi-source model approach and used 
the DPM code to calculate dose was developed, validated, and benchmarked for the Varian 6 
MV and 10 MV photon beams.  Several patient dose distributions were contrasted against a 
commercial algorithm to provide a proof of principal to use as an application in monitoring 
clinical trial activity. 
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Chapter 1    Introduction 
 
 
1.1 STATEMENT OF PROBLEM 
The Radiological Physics Center (RPC) is one of three quality assurance (QA) offices 
funded by the National Cancer Institute (NCI) that provides quality audit services for 
institutions participating in NCI cooperative clinical trials.  In the past twenty years the number 
of quality assurance offices has been reduced by half, while the number of participating 
institutions has more than doubled to nearly 1,700.  In response to this increase in demand, the 
RPC has evolved to develop several programs to efficiently provide improved dosimetric and 
QA services to the clinical trial community.  These programs include on-site audit evaluations 
and remote audit tools.  The on-site evaluation includes interviewing the institution’s physics 
and oncology personnel, performing physical measurements of the therapy machines, and 
reviewing quality control procedures, basic machine dosimetry data, and patient dose 
calculations.  The remote audit tools include review of patient dose calculations, credentialing 
institutions for participation in specific protocols utilizing advanced radiotherapy technology, 
verification of reference beam output with thermoluminescent detectors (TLD), and evaluation 
of advanced technology treatments with anthropomorphic QA phantoms.  The anthropomorphic 
phantom remote audit tool using TLD and radiochromic film enables comparison between 
measurement of the actual delivered dose distribution and the institutions’ planned treatment 
which includes the dose calculation algorithm of the patient plan.   
Although measurement based comparisons have traditionally provided an acceptable 
assurance in determining an institution’s performance in terms of correct dose delivery, there 
has been growing concern that today’s advances in therapy equipment including multi-leaf 
collimators and dynamic wedges, and other advances in treatment technique conformality such 
as three-dimensional stereotactic radiotherapy and intensity-modulated radiation therapy 
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(IMRT), have pushed the limits of measurement uncertainty.
1
  In part, this is due to the 
common occurrence of steep dose gradients found in today’s conformal treatments comprised 
of multiple segmented fields delivered per gantry angle.  In addition to the uncertainties 
associated with TLD and radiochromic film, the RPC has published the results from their 
remote anthropomorphic phantom audit program detailing the ability of institutions that 
participate in clinical trials to conform to prescribed treatment plans.  The results also show a 
varying degree of compliance even for treatment plans from the same treatment planning 
system (TPS).
2-6
  The TPS dose calculation algorithm, the beam model commissioning process, 
and delivery may contribute to these discrepancies.  These differences have caused concern 
over an institution’s ability to consistently deliver IMRT treatments and/or perform consistent 
heterogeneous dose calculations for patients entered onto clinical trials.  The use of a trusted 
independent dose calculation such as, the Monte Carlo (MC) technique can help to improve the 
understanding of the dose delivered by bridging the gap between the actual dosimetry and the 
TPS’s predicted dose distributions.  Such a tool that is capable of being applied to a majority of 
patient plans across many institutions and linear accelerator platforms can aid in the reduction 
of dose uncertainty by providing a centralized dose calculation method for treatment 
verification and retrospective dose response analysis.  
The MC dose calculation method is a statistical method for numerical integration that 
relies on the probability distributions describing the individual interactions of electrons and 
photons in a given set of materials.  The simulation of the histories is tracked to provide the 
information about the average quantities, such as dose.  Several MC codes, such as EGS4
7
, 
MCNP
8
, and PENELOPE
9
 are widely available and have been extensively benchmarked.  The 
MC method in general is regarded as the most accurate computational method currently 
available for determining dose, especially in heterogeneous patient tissues such as the lung.
10
  
Much of the motivation for the need for MC dose calculations comes from the variations found 
in numerous reports comparing the more accurate MC dose calculation to the conventional 
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calculation methods, such as the correction based methods
11-16
 and the convolution 
superposition (CS) method.
17-19
  It is clear that correction based calculations, which do not 
account for lateral scatter and electron transport, tend to overestimate dose and underestimate 
the penumbra broadening in cases involving lung tumors.  It is not clear how significant the 
improvement in accuracy is for the MC method when compared to the CS method.  Arnfield et 
al
19
 did report on the improved accuracy of the MC method when compared to the SC method 
in the application of an 18 MV photon beam, but found little difference for a 6 MV photon 
beam when irradiating a lung equivalent slab phantom using a 4 x 4 cm
2
 field size.  Various 
studies have reported differences between the MC and SC methods when comparing patient 
plans.
12,13,20,21
  The MC method has found growing widespread use in medical physics to 
complement measurements and traditional analytical based numerical calculations.  Even 
though MC calculations have gained a great deal of attention in the medical physics research 
community recently, its progress has been slowed due to the enormous amount of 
computational power necessary to perform the dose calculations with the accuracy that is 
required in radiation oncology.  With time, it is expected that computing power requirements 
will be met making the MC dose calculation an efficient and common tool in a clinical setting.  
In the meantime, researchers have reported on alternatives to the pure computationally 
intensive MC method, e.g., EGS4, MCNP, and PENELOPE, in an effort to increase the speed 
of computing.
22
  
One such MC computational method, and the method of choice for this project, is the 
Dose Planning Method (DPM).
22
  This method was largely chosen because its source code is 
open to allow for modifications and interfacing.  DPM uses the standard condensed history 
model for electron transport referred to as a mixed class simulation scheme as described by 
Berger.
23
  Here, large energy transfer collisions are handled by direct sampling of the distance 
to next collision using the total electron interaction cross-section and small collisions are 
modeled by the continuous slowing down approximation (CSDA).  Photon transport for 
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photoelectric absorption, Compton scatter, and pair production is handled interaction-by-
interaction.  The transport mechanics have been reformulated to increase the computing speed 
by enabling large electron transport steps even across heterogeneous boundaries while adhering 
to the applied multiple scattering distribution theory.  DPM has been shown to reproduce 
electron beam dose distributions calculated with EGS4 and PENELOPE MC codes with 
differences of less than 1.25% and a statistical uncertainty on the order of 0.2% of the dose 
maximum using in a variety of different materials.
22
  DPM has recently begun to find increased 
clinical use.  The University of Michigan in-house treatment planning system (UMPlan) uses 
DPM in a variety of photon treatment planning studies.
24
 Recently, Fragoso et al
25
 have 
evaluated a preclinical version of an electron beam dose calculation algorithm from Pinnacle 
(Philips Medical Systems, Andover, MA) that employed DPM based on a parameterized beam 
model which included a primary electron source and a contaminant photon source.  They found 
differences were, on average, 2% or 2 mm between measurement and calculation.  However, 
differences of 3% to 4% were found in the off-axis profiles for the largest applicator sizes. 
The MC dose calculation requires a beam model of the linear accelerator (linac) to 
describe the photon fluence and energy distributions in the radiation field.  Three common 
beam model approaches
10
 include the full MC simulation of the geometry of the linac head 
including the MLCs, a multiple-source model derived from the original head simulation with or 
without modifications from measurements, and a multiple-source model whose analytical 
function parameters are derived by a standard set of measurements.  We have chosen to apply 
the latter, a parameterized multi-source model derived from a standard set of measurements, for 
its simplicity and generic applicability.  Using a parameterized source model approach 
facilitates the unique representation of a particular linac make.  This is not easily done using the 
traditional MC codes such as EGS4 and MCNP that require detailed drawings defining a 
particular make of linac in order to describe the treatment head geometry and material 
composition.  Coupling this source model to DPM provides a generic solution for an 
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independent dose calculation tool.  Originally developed by Joseph Deasy and his research 
group at Washington University in St. Louis, the multiple-source model is comprised of three 
sources; a primary source, an extra-focal source, and a source for electron contamination.
26
  The 
primary point source represents isotropically distributed primary photons from the target.  This 
distribution is modified by the horn-effect using a piecewise linear function to represent the 
increase of fluence as the off-axis angle increases due to the flattening filter selectively 
absorbing a number of lower energy photons near the central axis as a function of the filter 
thickness.  As a result, the average mean energy becomes lower as the off-axis angle increase 
(off-axis softening).  The off-axis softening is accounted for by relating the off-axis half-value 
layer (HVL) as a function of the off-axis angle.
27
  The photon energy spectrum is described by 
the product of the Fatigue-Life distribution
28
 and the Fermi function [Equation 1].   
 
2
F
E-μ β
-
β E-μ-1exp
2 γ
E-μ β
+
β E-μ 1
f(E)=
E-E2γ E-μ 2π
1+exp
kT
    (1) 
where, E > μ; γ, β > 0    
 
We refer to this combined photon energy spectrum distribution as the Fatigue-Fermi 
distribution (FFD) where E is the photon energy, EF is the cut-off energy, μ, γ, and β are 
coefficients that shape the photon energy spectra.  Note that within the FFD function, the 
probability density function in the form of,
2
-xexp
2
2π
, of the standard normal distribution is 
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expressed.  This fitting function was selected from among an array of possible statistical 
distribution functions for its ability to fit the nine different photon spectra from various linac 
manufacturers based on simulations using the general purpose Monte Carlo code, BEAM, 
performed by Sheikh-Bagheri and Rogers.
26,29
  The extra-focal disk source, located at a distance 
consistent with the location of the flattening filter, represents exponentially distributed photons 
consistent with the filter radius and are generated or scattered within the head (primary 
collimator, flattening filter, jaws, etc) of the modern Varian linac
30
 (not necessarily specific for 
the modern Elekta or Siemens machines).  The extra-focal source applies the same FFD 
function as shown in equation 1 to describe its photon spectrum, however the FFD is scaled 
down to represent the reduction in energy due to the scattered and secondary photons.  The 
electron contamination source, located at a plane consistent with the bottom of the flattening 
filter, comprises a circular disk of uniformly distributed electrons created within the head.  The 
electrons from the third source have an exponential energy distribution as described by Fippel 
et al
31
 for Elekta and Siemens linacs, but presently is being applied to the Varian linac for this 
project.    
The source model commissioning, a two-step optimization process, is performed one 
time for each modern linac make and energy.  The justification for this is the fact that the vast 
majority of modern accelerators of the same make, model and energy have very similar 
dosimetry parameters.  The first step in commissioning the source model is based on a 10 x 10 
cm
2
 field size and the second step is based on a 40 x 40 cm
2
 field size.  In the first step, 
differences between the MC calculated dose and the measured dose using the data from the 
percent depth dose (PDD) and profiles at several depths in water for a 10 x 10 cm
2
 field size are 
minimized by adjusting model parameters.  The model parameters include: the FFD parameters, 
the scaled extra focal FFD factor, a global dose scale factor,
32
 the electron contamination 
relative fluence factor, and a blurring parameter to account for the smearing of dose from ion 
chamber volume effects that are apparent in profile measurements.
33
  In the second step, 
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differences between the MC calculated dose and the measured dose using the data from the 
profile at dmax in water for a 40 x 40 cm
2
 field size are minimized by adjusting the model 
parameters for a piecewise linear function that represents the increase in fluence as the off-axis 
angle increases (the horn-effect).  A fluence map is generated from the MLC positions that are 
imported from the DICOM plan file.  The map considers leaf transmission, interleaf leakage, 
and the effect of transmission from the rounded leaf ends.  To compensate for the assumption 
that the primary source is a point source, the MLC positions are retracted by an amount 
consistent with a finite sized source.  The completed fluence map is divided into beamlets based 
on areas of similar monitor unit weighting.  Corrections for photon fluence changes from the 
extra-focal source and fluence changes in electron contamination relative to changes in the field 
size are taken into consideration.  
Built around the source model and the DPM dose calculation is a graphical user 
interface (GUI).  The GUI was designed in the software application Matlab (MathWorks Inc., 
Natick, MA) and runs off the Computational Environment for Radiotherapy Research (CERR) 
software platform developed at Washington University.
34
  CERR was developed so that 
researchers in the radiotherapy community could share results in treatment planning.  The 
platform provides a common data structure for the creation of multi-institutional treatment plan 
databases for various types of research studies, including dose-volume-outcome analysis and 
IMRT treatment planning comparisons.  For instance, Pinnacle treatment plans are imported 
directly into CERR so that all of the necessary information about the plan can be is available 
for the DPM dose calculation.   
The basis for this project was established by a desire to generate an independent dose 
calculation tool built within CERR using the DPM code for which the initial version of the 
source model code was for the modern Varian linac (6 MV photon beam commissioned to 10 x 
10 cm
2
 only).  This project as described here completes the development, validation, and 
benchmarking of the Varian 6 MV photon beam and extends the DPM source model calculation 
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tool to provide a generic solution for both the Varian 6 MV and 10 MV photon beams as an 
independent dose calculation tool capable of computing dose accurately for a variety of 
homogeneous and heterogeneous treatment plans.  
Because of the source model’s flexibility in simulating the output of a linear accelerator 
by the optimization of analytical parameters, the source model can be developed for other 
machines and other energies.  Although not within the scope of this project, future work would 
be to continue development of source models to provide models for the Elekta and Siemens 
linacs at 6 MV and 10 MV photon energies.  Other energies, such as 18 MV, can also be 
included. 
 
1.2 BENEFITS TO SCIENCE 
The goal of this project, using DPM and the multiple-source model approach, as a 
generic dose calculation tool, is to provide a solution for the RPC to address past, current, and 
future clinical trial quality assurance issues.  Further development beyond the Varian 
accelerators would enable the RPC to apply this tool as part of their standard quality audit 
procedures when reporting to the treatment community the outcome of clinical trial quality 
assurance studies.  Specifically, the development of an independent dose calculation audit tool, 
receiving input plan information from a treatment planning system via CERR, will: 
i) Provide the framework to perform retrospective clinical outcome analysis by 
recomputing patient doses using a common independent dose calculation algorithm. 
ii) Complement the measurement-based anthropomorphic phantom remote audit 
program by providing an additional data set to compare to the TPS calculated dose 
iii) Supplement the overall quality assurance program by providing direct 
comparison of patient plans entered into current or retrospective clinical trials.  This eliminates 
any potential errors associated with the remaining steps of the treatment plan, such as record 
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and verify.  And, in the case of phantoms, it also eliminates the phantom set-up uncertainty.  
Here, the performance of the TPS dose calculation, dependent on the institution’s beam model, 
is isolated. 
iv) Facilitate the determination of treatment planning system performance that is 
unknown today.  Reports by the RPC 
2-6
 show that the variation in TPS calculations as 
compared to measurements from the RPC’s QA anthropomorphic phantom can be large due to 
improper beam modeling, planning errors, and phantom set up mistakes.  This variation in TPS 
performance is difficult to understand because each analysis from each institution is unique and 
independent.  A single treatment plan planned on a specific TPS could be imported at any 
institution with the same TPS and recalculated.  The resulting dose distribution could then be 
compared against the dose distribution calculated by the baseline DPM/source model tool.  
Given this scenario, TPS dose calculation performance and the dependency of the institution’s 
beam model could be delineated. 
 
1.3 HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis:  
A quality assurance tool based on the Monte Carlo Dose Planning Method (DPM) and 
coupled to a measurement-based source model can be developed to predict dose within 
3%/2mm of measurement for IMRT and stereotactic treatments planned on the Varian linear 
accelerator at the photon energies of 6 MV and 10 MV. 
 
Specific Aim 1:  Complete the development of the Varian 6 MV photon beam source 
model.  Modify the developed 6 MV source model to include a source model for the Varian 10 
MV photon beam. Validate the Varian 6 MV and 10 MV photon beam source models.  The 
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accuracy of calculated data consisting of percent depth dose and profiles up to a field size of 20 
x 20 cm
2
 is to be within 2%/2mm of measurement in at least 90% of the data tested. 
Specific Aim 2:  Benchmark the validated source models in specific aim 1 against 
measurement using anthropomorphic phantoms planned as IMRT homogeneous head and neck, 
stereotactic lung, and IMRT lung treatments.  The accuracy of the algorithm is to be within 
3%/2mm of measurement in at least 85% of the data tested. 
 
Specific Aim 3:  Benchmark the Pinnacle TPS calculation against the validated and 
benchmarked source models for the Varian 6 MV and 10 MV photon beams using the patient 
plans.  Dose volume histograms and dose profiles will be presented and compared. 
 
1.4 DISSERTATION ORGANIZATION 
Chapters 2 through 4 are each self-contained studies, including an introduction, 
material and methods, results and discussion, and conclusion. These chapters describe the steps 
of work required to address the specific aims and complete the project. Chapter 2 answers 
specific aim 1 and 2 with respect to the Varian 6 MV photon beam.  Within Chapter 2, the 
development, validation, and benchmark are presented.  Chapter 3 is similar to Chapter 2 but 
the validation and benchmarking of the Varian 10 MV model is presented.  In addition, chapter 
3 discusses an extension of the electron contamination model which was not presented in 
Chapter 2 because of its negligible contribution to the Varian 6 MV model.  Chapter 4 
addresses specific aim 3 by performing patient dose calculations on a number of treatment sites 
planned with the Varian 6 MV and the Varian 10 MV photon beams.  Within Chapter 4 a 
commercial calculation algorithm is used to compare against the MC dose calculation.  Chapter 
6 is a summary of the research project as a whole, and an evaluation of the hypothesis.  Chapter 
7 is the Appendix for the supporting data not presented in the aforementioned chapters. 
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Chapter 2 Development, Validation, and Benchmark: 
Varian 6 MV 
 
 
2.1 INTRODUCTION 
Motivated by its high degree of accuracy, the use of the Monte Carlo (MC) method in 
dose calculations has been extensively reported.
22,35-38
  By applying known probability 
distributions that govern the interactions of electrons and photons, the individual particle 
histories can be tracked with a high degree of certainty.  In general, today’s analytical dose 
calculation algorithms such as the convolution superposition algorithm found in commercially 
available treatment planning systems (TPSs) are very good at determining dose accurately.  
However, there are situations, such as patient heterogeneities (within the lung) and complicated 
deliveries of small fields or steep dose gradients, in which dose differences between the 
convolution superposition (CS) algorithm and the MC method exist.
17-19
  The ability to measure 
these complicated dose distributions in anthropomorphic phantom simulations is also a 
challenge.  The MC method is uniquely positioned to bridge the gap between dosimetry and the 
TPS’s predicted dose distributions as an independent method for determining dose.   
The traditional approach to applying the MC method requires a detailed knowledge of 
the treatment head geometry.  Depending on the quantities of interest and desire for accuracy, 
the extent to which the treatment head geometry is defined is a key component of the 
simulation.  For instance, in-field dose distributions can be accurately modeled by only defining 
the beam-line components such as target, flattening filter, jaws, MLC, and ion chamber.  
However, if the out-of-field dose needs to be studied, additional modeling of the primary and 
secondary collimators, and the shielding and structural components of the accelerator need to 
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be defined.  This can become a tedious and tenuous effort due to the level of detail and access 
to this information, as it is not always readily available from the manufacturer.   
Additionally the MC method has been slow to be implemented into the clinic because it 
has been historically very time consuming due to its computationally intensive nature.  Speed 
considerations are becoming less of an issue due to faster computers.  As a result, alternate 
approaches using MC have been studied and developed.
22,35-38
  The American Association of 
Physicists in Medicine’s Task Group Report No. 105 (TG-105) has described general schemes 
that outline three approaches.
10
  The first approach is the simulation of the accelerator treatment 
head resulting in phase-space information of the physical interactions.  The second involves the 
use of a multiple-source model with parameters derived from the initial simulation and stored 
phase-space information.  And finally the third relies on the use of measurements to derive 
parameters of analytical functions that describe a multiple-source model. 
We have reported on a versatile source model using the Dose Planning Method (DPM) 
Monte Carlo dose calculation algorithm for the Varian 2100 series linear accelerators (Varian 
Medical Systems, Inc., Palo Alto, CA) for the 6 MV photon beam.
26
  This conference series 
paper described the model, presented an analytical function used to describe the energy 
spectrums of many different linear accelerators and energies, and presented initial benchmark 
test results.  Briefly, the measurement-driven source model consists of three sources: one, the 
primary photon isotropic point source; two, an extra-focal disk source
30
; and three, an electron 
contamination uniform disk source
31
.  Since lower energy photon beams contain low amounts 
of electron contamination, this source is sometimes not considered.  The model also accounts 
for fluence and off-axis energy
27
 effects due to the flattening filter.   
Modifications to the model were necessary to complete the validation of the 6 MV 
photon beam for the field sizes between 4 cm x 4 cm and 40 cm x 40 cm and to improve the 
benchmark evaluations in order to achieve better agreement.  This work details those 
modifications and reports the results of the validation and benchmarking testing of the Varian 6 
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MV photon beam source model with DPM dose calculation engine, hereafter referred to as the 
source model.  The validation testing compared ion chamber measurements of dose profiles and 
percent depth doses (PDDs) to the source model calculation for square field sizes.  The 
benchmark testing used the Radiological Physics Center’s (RPC’s) anthropomorphic phantoms 
that house thermo-luminescent detectors (TLDs) and radiochromic film (Figure 2.4).  Under 
this testing, the entire model, including the multi-leaf collimator (MLC), was evaluated using 
realistic treatment plans.  These treatment plans where designed so that homogeneous and 
heterogeneous media were considered using highly modulated fields and small fields. 
  
2.2 MATERIAL AND METHODS 
2.2.1 Source model 
2.2.1.1 Hardware 
The dose calculations were performed using a Hewlett Packard ProLiant DL585 G5 
3.2-GHz Server with 16 AMD Opteron™ processors and 32GB of RAM (Hewlett-Packard 
Company, Palo Alto, CA).  The computation time was decreased by dedicating each beam 
defined in a treatment plan to a processor.  Each simulation used 10 million particles per square 
centimeter beamlet.  The calculations applied low energy electron and photon cutoffs of 200 
and 50 keV, respectively. 
2.2.1.2 Source model commissioning 
The source model commissioning process as described by Davidson, et al
26
 consisted of 
two main steps shown in Figure 2.1and Figure 2.2.  The first step was based on a 10 cm x 10 
cm open field.  The process consisted of separate dose calculations that were performed for the 
primary and extra-focal sources using energy bins of 0.25 MeV increments over the range of 
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energies that make up the energy spectrum for the nominal accelerating voltage of the linear 
accelerator.   
DPM Calculation 
using energy bins 
(0.25 MeV)
Optimize
Measurement: 
10 x 10 cm2 PDD, 
dose profiles
Parameters for fitting 
functions determined
Multi-source model
•Primary
•Flattening Filter 
•e- contamination
Based on 
measurements 
in water
Continue:  
Horn-effect 
coefficients
 
Figure 2.1 Step one of the source model commissioning process. 
 
 
The energy bins were varied within boundary constraints until the difference between the DPM 
calculation and the measurement was minimized.  Lower energy photon beams contain low 
amounts of electron contamination.  For the 6 MV photon beam, published work indicates that 
the contribution from electron contamination is less than one-half percent.
29
    Therefore, it was 
decided not to include the electron contamination source for the Varian 6 MV photon beam.  
Seven parameters used to describe the source model were determined during the first step of 
commissioning.  These parameters describe the primary and secondary energy spectrums, the 
relative fluence contributions from the extra-focal source and the electron contamination 
source, and a parameter that is used to describe the penumbra effects from the use of an ion 
chamber in the open field profile measurements.   
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Optimize 
beamlet 
weights
Measurement:     
40 x 40 cm2
dose profiles
Horn-effect coefficients 
determined
DPM beamlet calculation 
(using known parameters)
Continue:  
Horn-effect 
coefficients
 
Figure 2.2 Step two of the source model commissioning process 
 
In the second step of the commissioning process, the horn-effect model was 
represented by a piecewise linear function whose coefficients were determined by an 
optimization process.  A large field size of 40 cm x 40 cm was used to model the increase in 
fluence as a function of the off-axis angle.  For this step, the calculation was divided into 1 cm 
x 1 cm beamlets.  Each beamlet contribution was adjusted via the optimization routine until the 
difference between the calculated profile and the measured profile was minimized.     
The primary source and extra-focal source spectra were represented by a fatigue life 
distribution function combined with a Fermi function [Equation 1] and were described in 
Chapter 1.  The analytical functions that describe the spatial distributions of the secondary 
sources
30
 as well as the off-axis softening
27
 were implemented directly and without change.  A 
final conversion factor was applied to convert energy per photon to dose.  To avoid the 
statistical uncertainties of a single normalization point, the conversion factor was determined by 
normalizing to an integral dose defined by the area under the curve from the measured PDD 
between the depths of 5 cm to 15 cm for the 10 cm x 10 cm open field.
32
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2.2.1.3 Fluence map 
A fluence map, or monitor unit map, was formed at the distance to isocenter from the 
field size defined by the jaw settings.  The map was dependent on the position of the MLC 
leaves that comprised each segment, the transmission through the leaves, the effect of the 
transmission through the rounded leaf ends, and the leakage between adjacent leaves (interleaf 
leakage).  Specifically, the fluence map was divided into 1 mm by 1 mm regions.  The monitor 
units assigned to a given segment were recorded into each region that was exposed to the 
primary source.  Transmission through the MLC was defined as a percentage of the monitor 
units given for the segment.  This amount was recorded into the 1 mm by 1 mm regions that 
were unexposed to the primary source.  The transmission through the MLC leaves varies and 
increases as the thickness decreases near the leaf tip.  A piecewise linear function was used to 
model the rounded leaf ends.  The coefficients of the function were used to scale the monitor 
units in the region represented under the rounded leaf tip.  Essentially, this region was 5 mm by 
5 mm, which coincided with the width of the center leaves and the ‘length’ of the leaf tip.  In 
this way, the dose was blurred to improve the effect of the penumbra due to MLC rounded leaf 
ends.  The interleaf leakage was defined as a percentage of the monitor units designated for a 
given segment.  This amount was recorded alongside the location of one of the two leaves that 
comprised a 1 mm wide region of varying interleaf length.  The monitor units from all 1 mm by 
1mm regions from all segments for the beam were summed together and a final composite 
fluence map was constructed.  While the resolution of the fluence map was 1 mm by 1 mm, a 
finer resolution of 0.5 mm by 0.5 mm could be used requiring more beamlet calculations and 
therefore more computation time.  The DPM calculation was performed by segmenting the 
fluence map into calculation beamlets of similar monitor units.  
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2.2.1.4 Primary source size 
As stated earlier, the primary source was modeled as a point source.  However, the 
primary source in reality was known to have a finite dimension of about 1 mm in full width half 
maximum (FWHM).
39-42
  The effect of the finite source was seen in the penumbra regions of 
the film measurements from the benchmark evaluations.  Currently, the model accounts for this 
penumbra effect by applying an offset of the MLC leaf positions.  The offset was a fixed 
amount defined by the source radius and the distance from the source to the MLC (Figure 2.3).   
sr = 0.096xpen 
FS
51 cm
xpen
100 cm
xmlc
leaf
source
 
Figure 2.3 MLC offset position, xpen, with relationship to source size, sr.  The position of the 
MLC leaf, xmlc, is shown for reference. 
 
 
2.2.1.5 Machine output correction 
The model incorporated a hyperbolic equation that corrected for the machine output 
versus field size.
43
  Similar in concept to that described in the Pinnacle Physics Reference 
Guide
44
 (Philips Medical Systems, Andover, MA), a second-order hyperbolic equation with 
three constants sought to correct for the machine output as the ratio between the measured 
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output factor and the calculated output factor for a given field size.  The correction was applied 
to the three-dimensional (3D) dose matrix following the dose calculation. 
 
2.2.2 Anthropomorphic phantoms and dosimeters 
The homogeneous head and neck phantom of Figure 2.4(a) was made of acrylic and 
included an insert made of polystyrene.  Within the insert was solid water material that 
represented the primary target and the secondary target (node or parotid gland), and acrylic was 
used to represent the critical structure (spinal cord).  The heterogeneous thorax phantom seen in 
Figure 2.4(b) consisted of a high density polyvinyl chloride (PVC) housing, a nylon heart, a 
polybutylene terephthalate polyester (PBT) spinal cord, CIRS exhale lung material 
(Computerized Imaging Reference Systems, Inc., Norfolk, VA), a nylon target located in the 
medial-anterior direction of the left lung, and water used to fill the remaining volume.   
  
Figure 2.4 (a) The RPC head and neck phantom.  (b) The RPC thorax phantom 
 
The details of the design and use of these phantoms can be found elsewhere in the 
literature.
45,46
  Presently, the DPM code allows up to five material definitions.  The material 
properties defined in the DPM code originated from user input of the elemental composition, 
atomic number, and density of a specific material.  The code extracts the raw physics data from 
a library of constants, and produces the cross-sectional information.  Air, polystyrene, water, 
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solid water, and acrylic were defined for the head and neck phantom while air, CIRS lung, 
water, nylon, and PVC were defined for the thorax phantom. 
The head and neck phantom and thorax phantom housed TLD capsules and 
radiochromic film.  The TLD capsules (TLD-100 capsules, Radiation Detection Company, 
Gilroy, CA) were located at the center of the target(s) and within the critical structure(s) to 
collect near-point absolute dose information. For the head and neck phantom, four capsules 
were used for the primary target, two capsules were used for the secondary target, and two 
capsules were used for the critical structure.  For the thorax phantom, two capsules were used 
for the target and two capsules were used in each critical structure (heart and spinal cord).  The 
films were strategically located in close proximity to the primary target TLD capsules so that 
the films’ intersection coincided with the center of the primary target and the films were 
normalized to the TLD values.  The normalization was defined as the average of the ratio of 
each target TLD dose value to the dose value of the adjacent film region.   
All three major planes were represented by the films for the thorax phantom while the 
films for the head and neck phantom were positioned only in the axial and sagittal planes.  EBT 
radiochromic film was used for the deliveries of the IMRT head and neck plan and SBRT lung 
plan.  MD-55 was used for the delivery of the IMRT lung plan (EBT and MD-55 radiochromic 
film, International Specialty Products, Wayne, NJ).  All films were read using a densitometer 
with a CCD camera and light source (Photoelectron Corporation (defunct), Lexington, MA).  
For each batch of film, a sensitometric curve was established to relate the film optical density 
(OD) to dose. 
 
2.2.3 Validation testing 
The validation of the Varian 6 MV photon beam was performed by comparing 
calculated values to the measured values of the basic beam data.  These data consisted of the 
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percent depth dose and the dose profiles at several depths from several field sizes.  The depths 
of the dose profile comparisons were 1.5 cm, 6 cm, 12.5 cm, and 22 cm in a water phantom.   
The field sizes included 4 cm x 4 cm, 5 cm x 5 cm, 6 cm x 6 cm, 8 cm x 8 cm, 10 cm x 10 cm, 
15 cm x 15 cm, 20 cm x 20 cm, 25 cm x 25 cm, and 40 cm x 40 cm.  The simulated water 
phantom had dimensions of 50 cm x 50 cm x 50 cm.   
The calculated data were extracted from the 3D dose matrix relative to the location of 
the surface of the water phantom.  This location was the region of interest defined by the skin 
contour.  The resolution of the calculated data was 0.2 cm in the depth direction.  This direction 
was defined in the CT data set as the y-direction.  The x-direction, or lateral direction, was also 
0.2 cm and the z-direction, or in-plane direction, was the slice thickness of 0.3 cm.  The 
measured data was the same data used for the beam model commissioning of the clinical 
treatment planning system (TPS).   
The measured values were made using a small volume ion chamber (0.04 cm
3
 internal 
volume).  To account for the volume effects of the ion chamber which tend to smear the dose 
and exaggerate the dose penumbra, a Gaussian convolution was applied to the calculated dose 
data for all profile comparisons.
33
  The standard deviation of the Gaussian kernel was one of the 
seven parameters determined in the model optimization process described above.   
The accuracy of the calculated data compared to the measured data (PDDs and dose 
profiles) for field sizes from 4 x 4 cm
2
 to 40 x 40 cm
2
 was tested to a gamma criterion of 2% of 
the maximum dose and 2 mm distance to agreement.  In addition, local dose differences were 
studied at depths beyond dmax and in the high dose regions of the dose profiles.  The high dose 
region within a dose profile at a specific depth was defined by the dose greater than or equal to 
80% of the dose at the central axis.
47
  Quantifying the distance-to-agreement for the location of 
the calculated dmax relative to the measured dmax was also evaluated.   
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2.2.4 Benchmark testing 
The validated source model was benchmarked under a variety of conditions.  Designed 
to be progressively more difficult, treatment plans were evaluated for homogeneity, 
heterogeneity, small fields, and highly modulated fields.  The RPC’s anthropomorphic IMRT 
head and neck phantom was used to test a highly modulated delivery of nine coplanar beams 
which comprised of 72 segments to a homogeneous medium (Figure 2.1(a)).  The RPC’s 
anthropomorphic thorax phantom was used to test a nine beam SBRT plan and a five beam, 63 
segment non-coplanar IMRT plan (Figure 2.1(b)).  The IMRT head and neck plan and SBRT 
lung plan were designed using the credentialing guidelines and irradiation instructions 
employed by the Radiation Therapy Oncology Group (RTOG) to credential institutions for 
participation in specific advance technology protocols.  Each plan was delivered three times to 
evaluate the repeatability.   
The resolution of the DPM calculation was governed by the size of the CT voxel.  For 
this work, the voxel size was 0.195 cm by 0.195 cm by 0.25 cm for all treatment plans studied.  
The accuracy of the DPM calculation was determined by comparing point doses, dose profiles, 
and 2D gamma maps to the measured data.   
2.2.4.1 Point dose comparisons 
Point dose comparisons were made between the calculated values and measured TLD 
values of the target and critical structure locations.  The measured point doses were defined by 
the small volume of TLD powder inside the capsule while the respective calculated point doses 
were derived from the small regions of interest contoured from the CT scan.   
2.2.4.2 Dose profile comparisons 
Dose profiles along the major planes intersecting the center of the targets were 
qualitatively evaluated between the calculated and measured film values.  The superior-inferior 
profiles were extracted from the sagittal film plane for the head and neck planned deliveries and 
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from the coronal film plane for the lung planned deliveries.  Since the sagittal and coronal film 
planes are composed of a separate superior portion and a separate inferior portion due to the 
intersecting axial film plane, the plotted profiles showed a discontinuity of the measured dose 
within the center of the target.  The profile plot was meant to be interpreted qualitatively, 
although quantitative information existed, the reader should ignore the measured data in this 
limited central region as demonstrated in Figure 2.5.   
 
 
Figure 2.5 Asterisk (*) indicates the region of the axial cross plane where separation exists 
between superior portion and inferior portion of sagittal or coronal film 
 
2.2.4.3 Gamma map comparisons 
2D dose distributions were evaluated using the gamma index method
48
 where 
quantitative results were recorded and used to test the hypothesis.  The accuracy of the 
calculated data compared to the measured film data from the major planes intersecting the 
targets was tested to a gamma criterion of 3% of the target TLD dose and 2 mm distance to 
agreement. 
Some regions of the gamma map have no measured dose because the test region 
encompassed more area than the film.  Typically, larger regions that were maroon in color and 
that were fairly rigid and defined were most likely regions outside of where the film was 
located.  For instance, the sagittal and coronal films of the thorax phantom had these regions 
along the central A-P and lateral directions, respectively, and in the S-I direction to provide 
* 
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clearance from one another to coincide with the axis they shared (Figure 2.6).  The sagittal film 
for the head and neck phantom also had a region that was cut away to accommodate the spinal 
cord critical structure (Figure 2.7).  The axial film for the head and neck phantom had a small 
region in the posterior, right lateral corner that was cut away to allow proper assembly of the 
target insert.  These regions were included in the initial gamma analysis, but a subsequent 
estimate of the data in those regions allowed for a correction to be made to the final results. 
 
  
Figure 2.6 Gamma Map.  The regions outlined in ‘white’ represent the estimated area that was 
not included in the gamma index calculation. The left figure is a representative coronal plane 
and the right figure is a representative sagittal plane from the thorax phantom. Scale:  1 mm = 
0.65 mm 
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Figure 2.7 Gamma Map. The regions outlined in ‘white’ represent the estimated area that was 
not included in the gamma index calculation. The figure is representative of the sagittal plane 
from the head and neck phantom. Scale:  1 mm = 1.09 mm 
 
2.2.4.4 Treatment plans 
All treatment plans were planned using the Pinnacle treatment planning system 
(version 7.6c or higher) (Philips Medical Systems, Andover, MA).  The dose prescription and 
dose constraints were met based on the calculated dose using Pinnacle’s collapsed cone 
convolution algorithm.   
For the head and neck plan, at least 95% of the primary planning target volume (PTV) 
received 6.6 Gy and less than 1% of the primary PTV received less that 93% of the prescribed 
dose.  At least 95% of the secondary PTV received 5.4 Gy and less than 1% of the secondary 
PTV received less than 93% of the prescribed dose.  The PTV was constrained to the gross 
tumor volume (GTV).  The organ at risk received less than 4.5 Gy.  The dose to the normal 
tissue received no more than 7.26 Gy.  The targets and the organ at risk (critical structure of the 
spinal cord) are shown in Figure 2.8. 
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Figure 2.8 Transverse slice through the center of the targets of the head and neck phantom.  
Contour colors are as follows: red (primary target); aqua (secondary target); violet (critical 
structure, spinal cord).  Note the dark dots are the TLD measurement locations. 
 
The PTV for the SBRT lung plan was the GTV plus 0.5 cm in the axial plane and plus 
1 cm in the longitudinal plane.  At least 95% of the PTV received 6 Gy and at least 99% of the 
PTV received 5.4 Gy.  The maximum dose received at 2 cm and beyond from the PTV was no 
more than 3.5 Gy.  The dose to the PTV was within 60% and 90% of the maximum dose.  The 
prescription isodose volume to PTV ratio was less than 1.2 and the ratio of 50% of the 
prescribed isodose volume to PTV was less than 3.6.  Figure 2.9 is a transverse CT slice 
through the center of the target showing the GTV and critical structures within the anatomy of 
the thorax phantom. 
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Figure 2.9 Transverse slice through the center of the target of the thorax phantom.  Contour 
colors are as follows: green (GTV); aqua (critical structure, heart); violet (critical structure, 
spinal cord).  Note the dark dot in each of the three regions is the TLD measurement location.  
The TLD location for the target is adjacent the center in the posterior-lateral distal direction.  
 
For the IMRT lung plan, the PTV was the GTV plus a 1 cm margin.  The prescription 
was to deliver 66 Gy to at least 95% of the PTV in 33 fractions.  The maximum dose prescribed 
to the spinal cord was 45 Gy.  No more than 40% of the total lung was to receive more than 20 
Gy.  The dose to the entire heart was not to exceed 40 Gy or no more than 50% of the heart was 
to receive more than 50 Gy.  MD-55 radiochromic film is sensitive in the range of 20 Gy, 
therefore an equivalent of 10 fractions was delivered from this plan and the prescription dose 
was adjusted accordingly. Figure 2.9 shows the location of the PTV within in the lung and the 
heart and spinal cord critical structures.  
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2.3 RESULTS AND DISCUSSION 
2.3.1 Source model 
2.3.1.1 Source model commissioning parameters 
The seven model parameters that describe the photon energy spectra, fluence 
contributions, and the penumbra measurement effect for the first step of the commissioning 
process for the Varian 6 MV photon beam are shown in Table 1.  The first three parameters, , 
, and , defined the spectrum shape, relative peak energy location, and relative scale, 
respectively, of the fatigue life distribution function.   
Parameter Value 
Fatigue-Life distribution shape parameter,  1.75 
Fatigue-Life distribution location parameter,  -0.0165 
Fatigue-Life distribution scale parameter,  3.50 
Primary spectrum to extra-focal spectrum reduction scale factor 1.7 
Extra-focal fluence relative to the primary fluence 0.13 
Electron contamination contribution (relative to the primary photon 
contribution) 
0.002 
Standard deviation of Gaussian used to convolve the MC dose profile to 
match the measured dose profile during the validation process 
1.2 
 
Table 1 Parameters of the commissioned source model for spectra, fluence, and profile 
penumbra measurement effect.  
 
 
A plot of the energy spectrum compared to the energy spectrum computed using the 
widely accepted BEAM code
29
 for simulating radiation transport in accelerators is shown in 
Figure 2.10.  Clearly, the commissioned source model spectrum was not ideal compared to the 
BEAM code, but provided an adequate representation of the photon beam based on the 
validation.  The extra-focal energy spectrum was scaled in energy by a factor of 1.7.  The 
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relative fluence of the extra-focal source was 13% of the primary source fluence for the 10 cm 
x 10 cm open field.  The dose contribution from the electron contamination source was less 
than one-half percent (0.2%) of the primary dose and was not included in the model because of 
its minor contribution.  The standard deviation of the Gaussian function used for the dose 
smearing convolution was 1.2 mm. 
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Figure 2.10 Varian 6 MV spectrum:  Commissioned source model compared to BEAM 
spectrum
29
  
 
The results of the second step of the commissioning process are shown in Table 2.  The 
horn-effect coefficients of the piecewise linear function are shown as increases in the fluence 
weighting as a function of the cosine of the off-axis angle. 
  29 
 
 
Cosine(off-axis angle) Fluence weight increase 
1.00000 1 
0.99970 1.0135 
0.99879 1.048 
0.99728 1.099 
0.99518 1.13 
0.99250 1.17 
0.98926 1.22 
0.98546 1.24 
0.98113 1.26 
0.97630 1.28 
0.97098 1.30 
0.96277 1.32 
 
Table 2 Coefficients of a piecewise linear function to describe the increase of fluence as the off-
axis angle increases (horn-effect) 
 
Following the completion of the two-step commissioning process, the final conversion 
factor that was applied to convert energy per photon to dose in cGy was 0.24442.  This factor 
was applied to every dose calculation performed for the Varian 6 MV source model. 
2.3.1.2 Fluence map, primary source size, and machine output correction 
In terms of transmission, the fluence map generation was unique to the beam energy 
and the MLC configuration characterized by the patient or phantom treatment plan.  For the 
Varian 6 MV photon beam, the transmission through the bulk of the MLC leaves was 1% 
while, the interleaf leakage was an additional 1% of the monitor units given for the particular 
segment.   
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The offset of the MLC leaf positions, xpen, which was necessary to compensate for the 
absence of a finite primary source size, was 0.4 mm.  The offset amount was fixed for the 
Varian accelerator as it has been reported that the source size was nearly the same regardless of 
energy.
39-42
  Based on the relationship of the source-to-MLC distance and the source-to-axis 
distance, the source diameter, sr, was 0.84 mm FWHM.    
Figure 2.11 shows the relationship between the output factor and the field size for the 
calculated and measured data.  A hyperbolic equation was determined to correct the calculated 
output factors.  This equation, 
3.95
1.12
22.81
y
x
, where y is the output correction and x is 
the field size was necessary to maintain the proper predicted machine output and which had 
been a deficiency of the model to completely describe the scatter conditions that change as a 
function of field size. 
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Figure 2.11 Output factor at dmax versus field size for the measured, calculated and corrected 
output.  A hyperbola curve was determined to correct the calculated values. 
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2.3.2 Validation testing 
2.3.2.1 Uncertainty 
The uncertainty of the dose determined for the ion chamber measurements was 
estimated to be 1.5% at one standard deviation.
49
  The estimate of uncertainty, or the standard 
error of the mean, for the simulation was 1% using 10 million particles per square centimeter.
10
   
2.3.2.2 Percent depth dose 
Comparisons of the measured percent depth dose (PDD) and the source model 
calculated PDD data for the Varian 6 MV photon beam were made for the field sizes between 4 
cm x 4 cm and 40 cm x 40 cm.  While all of the PDD comparisons are presented in the 
appendix (Chapter 6), three fields that represent the range of field sizes are presented here.  
Those fields are 4 cm x 4cm, 10 cm x 10 cm, and 40 cm x 40 cm and their data are shown in 
Figure 2.12, Figure 2.13 and Figure 2.14, respectively. 
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Figure 2.12 Calculated and measured percent depth dose curves at 6 MV for a 4 cm x 4 cm 
field. 
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Figure 2.13 Calculated and measured percent depth dose curves at 6 MV for a 10 cm x 10 cm 
field. 
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Figure 2.14 Calculated and measured percent depth dose curves at 6 MV for a 40 cm x cm 40 
field. 
 
Overall, for the open field tests along the central axis, good agreement existed between 
the calculated data set and the measured data set.  Beyond dmax, the mean of the local percent 
difference was within 1.0% for the fields from 4 cm x 4 cm (see Figure 2.12) to 15 cm x 15 cm.  
100% of all data tested for these fields were within the 2%/2 mm criteria.  Otherwise, for the 
larger field sizes from 20 cm x 20 cm to 40 cm x 40 cm (see Figure 2.14) the mean local 
percent difference was between 1.2% and 2.0% beyond dmax.  The minimum percentage of the 
all the data tested for these larger field sizes that met the criteria of 2%/2 mm, was 96%; and on 
average 97% of the data met the criteria.   
For the 4 cm by 4 cm field (Figure 2.12), the calculated dmax was 1.6 cm, while the 
measured dmax was 1.5 cm. The 40 cm x 40 cm field (Figure 2.14) showed the least agreement, 
where dmax was 1.6 cm for the calculated point versus 1.2 cm for the measured point.  The 10 
cm x 10 cm field (Figure 2.13), which was the field that was used to commission the source 
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model, dmax was 1.6 cm for the calculated point and 1.5 cm for the measured point.  For the 
larger fields, the few data points that fell outside the stated criteria tended to occur in the build-
up region where the calculation reported dose was less than the measured dose.  The model did 
not predict the shift in dmax to shallower depths and underestimated the dose in the build-up 
region as the field size increased.  This is a limitation in the model and is mainly due to the 
increased collimator scatter that occurred with an increase in field size and could be improved 
by including the small contribution from the electron contamination.
50
  Recall that the model 
was commissioned based on the conditions of the 10 cm x 10 cm field size and does not 
explicitly model the relative fluence and energy as a function of field size for the extra-focal 
source and also assumes that the primary source originates as a point.  Although a small 
contribution, the dose from electron contamination was not included in the commissioning of 
the 6 MV source model.  Another contribution to the disagreement between the calculation and 
measurement for the larger field sizes may be how the calculated data is extracted from the 3D 
dose matrix.  The percent depth dose calculated data relied on the resolution of the CT scan (0.2 
cm) and the accurate placement of the contoured region of interest which defined the water 
surface.  Since a steeper dose gradient exists as the build-up region and dmax shift toward the 
surface to shallower depths as the field size increases due to the increase in collimator scatter, 
agreement between the calculation and the measurement becomes more sensitive to an accurate 
registration of the surface location within the calculation algorithm.   
2.3.2.3 Dose profiles 
The dose profile data for the 6 MV photon beam are shown in Figure 2.15, Figure 2.16, 
and Figure 2.17 for field sizes of 4 cm x 4, 10 cm x 10 cm, and 40 cm x 40 cm, respectively.  
The dose profile comparisons for the remaining fields are presented in the appendix (Chapter 
6).   
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Figure 2.15 Calculated and measured dose profiles at 6 MV from a 4 cm by 4 cm field at depths 
of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 2.16 Calculated and measured dose profiles at 6 MV from a 10 cm by 10 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 2.17 Calculated and measured dose profiles at 6 MV from a 40 cm by 40 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Good agreement existed between the calculation and measurement for all field sizes at 
all depths.  As was the case for the percent depth dose comparisons, the dose profiles for the 
field sizes from 4 cm x 4 cm to 15 cm x 15 cm met the criteria of 2%/2 mm completely (Table 
3).  For the larger fields, the minimum percentage that met the criteria of 2%/2 mm, was 95%; 
and on average 98% of the data met the criteria.   
 
Field size 
(cm
2
) 
Minimum percentage of data meeting the 
criteria of 2% of dmax or 2 mm DTA 
(%) 
Average percent 
difference (local dose) 
(%) 
4  4 100 0.8 
5  5 100 0.6 
6  6 100 0.7 
8  8 100 0.6 
10  10 100 0.5 
15  15 100 0.8 
20  20 97 1.3 
25  25 99 0.9 
40  40 95 1.0 
Table 3 Dose profile agreement between calculated and measured data. Profiles are from the 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm for each field size. Minimum percentage of the 
data meeting the criteria of 2% of dmax or 2 mm DTA and the percent difference is the average 
of all local percent differences from all of the profiles for a given field.  
 
 
The average local percent difference in the high dose region defined by the measured 
dose values greater than or equal to 80% of the dose at the central axis was between 0.5% and 
1.3%.  Generally, the average differences were consistent regardless of the field size, although 
the larger fields did exhibit slightly less agreement.  The results of the gamma criteria and local 
dose comparisons of the high dose regions showed that the occasional disagreement was 
limited to the penumbra and low dose regions of the larger fields (see Figure 2.17) where 
scatter conditions offered their greatest contribution.  The dose profiles comparisons, like the 
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percent depth dose comparisons, suggested the extra-focal model, while very robust, was likely 
the single biggest contributor to the small inaccuracies of the model. 
 
2.3.3 Benchmark testing 
2.3.3.1 Uncertainty 
The uncertainty of the dose distribution as determined by the EBT film and TLD at one 
standard deviation was between 2.6% and 3.5%.  This is consistent with a previously published 
report using the same the methodology.
51
  TLD used as an absolute dosimeter helped to reduce 
the variation that can occur between the film calibration process and the actual film used in the 
phantom at the time of irradiation.  The estimate included the uncertainty of the TLD dose,
52
 
the film uniformity, the film-to-film variation, and the fit of the sensitometric curve.
53
  The 
TLD uncertainty was included because the film was normalized to the adjacent target TLD 
housed within the phantom.  The estimate of uncertainty, or the standard error of the mean, for 
the simulation was 1% using 10 million particles per square centimeter.
10
   
2.3.3.2 Effect of finite primary source size on benchmark deliveries 
Prior to presenting the results of the benchmark evaluation, the effect of the MLC 
offset is presented.  As described in Section  2.3.1.2 and in Figure 2.3, an MLC offset was 
applied to open each leaf position by 0.4 mm to compensate for the finite dimension of the 
primary source.  Rangel and Dunscombe performed a study where they looked at the dosimetric 
impact of MLC position errors in dynamic IMRT deliveries.
54
  They applied the equivalent 
uniform dose (EUD) metric to the dose volumes of targets and structures whose plans were 
compared with and without an MLC offset as a way to quantify MLC positional changes. They 
chose this metric for its applicability to treatment dosimetry since it is sensitive to both dose 
and volume.  The EUD describes the dose from a nonuniform dose distribution producing the 
same radiobiological effect as if it was the dose from a uniform dose distribution.  As expected, 
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an MLC offset in which the leaves are opened resulted in an increase in the EUD of an 
irradiated volume due to an increase in head and phantom scatter.  They found that for more 
highly modulated treatments, such as head and neck plans versus prostate plans, the increase in 
the EUD of the clinical target volume was an average of 2.8% versus 1.0% higher, respectively, 
given an MLC offset of an additional 0.5 mm opening for every modulated leaf.  Figure 2.18 
shows the frequency histogram of the aperture distances.  The aperture distance is defined as 
the distance between opposing leaf ends.  The histogram is the grouping of aperture distances 
used to form each static segment for each beam and was determined for each treatment plan.  In 
our studies, we found the EUD of the primary PTV in the head and neck plan was 2.4% higher, 
the EUD of the PTV in the SBRT lung plan was 1.7% higher, and the EUD of the PTV in the 
IMRT lung plan essentially unchanged when an MLC offset of 0.4 mm was applied.  While the 
IMRT head and neck plan was similar to their results and the SBRT lung plan was less affected, 
most likely due to less modulation, it is not completely clear why the IMRT lung plan remained 
unchanged.  With the additional opening from the MLC offset a higher output existed due to an 
increase in treatment head and phantom scatter.  Therefore, it may be reasonable to conclude 
the relationship between the MLC positional changes and the EUD of the PTV for low density 
phantom media is less sensitive due to a reduction in phantom scatter.   
  42 
0 10 20 30 40 50 60 70 80 90
0
100
200
300
400
500
600
Aperture size between opposing leaves (cm)
fr
e
q
u
e
n
c
y
 
 
IMRT head and neck
SBRT lung
IMRT lung
 
Figure 2.18 Frequency histogram of the aperture distances of opposing leaf ends from the 
IMRT head and neck plan, the SBRT lung plan, and the IMRT lung plan. 
 
 
2.3.3.3 Delivery of the IMRT head and neck phantom plan: Point dose comparisons 
The results of the point dose comparisons are shown for each TLD measurement 
location in Table 4.  Four TLD capsules were located within the center of the primary target, 
two TLD capsules within the center of the secondary target and two TLD capsules within the 
spinal cord critical structure.  Included in the table are the average dose measurements and the 
percent standard deviations from the three repeated irradiations.  The comparisons of the 
primary target, the secondary target, and the critical structure between the DPM calculation and 
measurement and between the Pinnacle calculation and measurement were expressed as a ratio.  
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Point 
dose 
local 
TLD measurement DPM calculation 
Pinnacle calculation 
(reference) 
Avg. 
(cGy) 
% std. 
dev. 
Avg. 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Avg 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Pri S-A 648 0.4 638 1.8 0.984 677 1.0 1.045 
Pri S-P 650 0.8 635 0.8 0.977 674 0.6 1.037 
Pri I-A 638 1.1 637 1.4 0.998 678 0.9 1.062 
Pri I-P 665 0.9 646 1.6 0.971 683 1.0 1.027 
Pri Avg     0.983   1.043 
Sec S 536 0.3 531 2.0 0.991 552 1.4 1.030 
Sec I 529 0.5 525 2.3 0.992 546 1.5 1.032 
SecAvg     0.991   1.031 
CS S 199 1.6 195 7.6 0.982 235 9.8 1.183 
CS I 201 1.2 176 6.7 0.877 206 6.2 1.026 
CS Avg     0.929   1.105 
Table 4 Point dose comparisons of the IMRT head and neck phantom.  The measured dose is 
the average dose from the three repeated irradiations.  Calculated results are from DPM.  The 
Pinnacle calculation is provided for reference. Point dose locations are keyed as follows:  Pri = 
primary target; Sec = secondary target; CS = critical structure; S = superior; I = inferior; A = 
anterior; P = posterior. 
 
The agreement between the DPM calculation and measurement for the primary target 
on average was 0.983.  The range of this averaged value was from 0.971 to 0.998. For the 
secondary target, both TLD locations showed that on average the calculation was slightly lower 
than the measurement by about 1%.  The critical structure showed the greatest deviation where 
the calculation for the superior TLD location underestimated the dose by 2% and for the 
inferior TLD location underestimated the dose by about 12%.  The larger differences between 
the calculated and measured dose were seen in their larger standard deviations.  This, in large 
part, was due to the high dose gradient region that existed between the critical structure and 
target.  It is also possible that the operation of the MLCs were in error.  Given the close 
proximity of the superior and inferior TLDs to one another, it is possible that the MLC leaf in 
line with the superior TLD was not the correct position.  In general, it is noted that the Pinnacle 
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calculation overestimated the dose in the targets so that the ratio between the calculation and 
measurement on average was 1.031 to 1.043.   
The results in Table 5 present the overall range and average of the ratios between the 
source model calculation and the measurement, and between the Pinnacle calculation and the 
measurement for the primary and secondary targets and critical structure for all TLD locations 
and all repeated irradiations and not as an average of the repeated irradiations as was the data 
contained in Table 4.   
Primary 
target
Secondary 
target
Critical 
structure
Primary 
target
Secondary 
target
Critical 
structure
high 1.006 0.997 0.997 1.071 1.037 1.202
low 0.966 0.988 0.865 1.021 1.026 1.013
avg 0.983 0.991 0.929 1.043 1.031 1.105
DPM calculation to measurement Pinnacle calculation to measurement
 
Table 5 IMRT head and neck:  The range and average calculation to TLD measurement ratio of 
the point doses for the primary and secondary targets and critical structure for DPM and 
Pinnacle.  The data is for each TLD location from each repeated irradiations. 
 
 
The benchmark evaluation was strictly between the validated source model and 
measurement.  The Pinnacle comparison with the measurement is shown only for reference and 
is representative of the comparison one might find between the source model calculation and a 
state of the art planning system. 
 
2.3.3.4 Delivery of the IMRT head and neck phantom plan: Dose profile and gamma map 
comparisons 
Dose profiles along all three major planes are shown in Figure 2.19, Figure 2.20, and 
Figure 2.21.  The dose profiles show the qualitative agreement between the source model DPM 
calculation and the measured dose and indicate the tendency of the calculation to slightly 
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underestimate the dose.  Good agreement is seen across all dose profiles. The DPM calculation 
responded to the subtle changes in dose delivery across the primary PTV as noted in the lateral 
profile of Figure 2.19.   
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Figure 2.19 IMRT H&N delivery single irradiation (number 2): Lateral dose profile. 
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Figure 2.20 IMRT H&N delivery single irradiation (number 2): A-to-P dose profile. 
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Figure 2.21 IMRT H&N delivery single irradiation (number 2): S-to-I dose profile. 
 
In conjunction with the dose profiles, the gamma maps at a test criterion of 3%/2 mm 
are shown in Figure 2.22 and Figure 2.23.  These figures report the results from a single 
irradiation.  Gamma maps at the criteria levels of 3%/2 mm and 5%/3 mm and dose profiles for 
all three repeated irradiations are presented in the Chapter 6 Appendix.    For the IMRT head 
and neck plan, the percentage of the data meeting the criterion of 3% or 2 mm for the gamma 
maps from the axial and sagittal dose planes intersecting the center of the primary target from 
all three repeated irradiations averaged 93% and ranged from 90% to 98%.  The gamma maps, 
which consider dose differences as a relative percentage and dose differences as a distance to 
agreement, showed that in general the calculation predicted the dose within the criteria in the 
high dose, high gradient, and low dose regions that lied along the axial and sagittal planes.  The 
dose profiles in conjunction with the gamma maps indicated that the modeling to describe the 
penumbra which applied an MLC offset, interleaf leakage, rounded leaf and leaf transmission 
factors in the highly modulated fields of the head and neck plan was correct.   
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Figure 2.22 IMRT H&N delivery single irradiation (number 2): Axial plane, gamma map tested 
to 3%/2 mm criteria, where 94% of the data passed.  Scale is 1 mm = 0.95 mm. Small circle 
outline represents the location of the secondary PTV, large crescent shaped outline represents 
the primary PTV, and the small red circle represents the spinal cord critical structure. 
 
Figure 2.23 IMRT H&N delivery single irradiation (number 2): Sagittal plane; gamma map 
tested to 3%/2 mm criteria, where 91% of the data passed.  Scale is 1 mm = 1.3 mm.  Rectangle 
outline represents the location of the primary PTV.  The maroon region in the vertical direction 
is where the film has been cut away to avoid interference with the critical structure region. 
 
 
Figure 2.24 shows the performance with and without consideration for the primary 
finite source, interleaf leakage, and the effect of the rounded leaf ends on transmission.  Note 
that in addition to an increase in the calculated dose to the primary and secondary targets, there 
was an improvement in the widening and shape of the penumbra.   
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a) Gamma map: 3%/2 mm (before) b) Gamma map: 3%/2 mm (after) 
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c) Lateral profile (before) d) Lateral profile (after) 
Figure 2.24 IMRT head and neck:  Gamma maps (a and b) and lateral dose profiles (c and d) 
from the same irradiation, but before (a and c) and after (b and d) changes to the model to 
improve the penumbra. 
 
For reference, the Pinnacle calculation was compared to the same measured data and is 
shown in Figure 2.25.  The results were somewhat surprising given that the delivery was made 
in a homogeneous phantom.  However, the results at 5%/3 mm show a marked improvement in 
agreement over the results at 3%/2 mm.  The lateral dose profile (Figure 2.25) shows somewhat 
steep gradients occurring frequently.  The dose grid calculation for Pinnacle plan was studied at 
0.4 cm and 0.2 cm.  No improvement was gained given the finer resolution.  The Pinnacle 
calculation commonly includes a post processed smoothing function which may account for the 
lack of the dose gradient changes in the Pinnacle calculation.  The dose profiles show that 
Pinnacle is overpredicting the dose in the primary and secondary targets when compared to the 
film measurement. 
  49 
  
a) Axial: 3%/2 mm, 61% pass; scale 1mm = 
0.79 mm 
b) Axial: 5%/3 mm, 86% pass; scale 1mm = 
0.79 mm 
  
c) Sagittal: 3%/2 mm, 60% pass; scale 1 mm = 
1.09 mm 
d) 5%/3 mm, 89% pass; scale 1 mm = 1.09 mm 
   
e) Lateral profile f) Anterior to posterior profile g) Superior to inferior profile 
Figure 2.25 Gamma map (a through d) and dose profile (e through g) comparisons between the 
Pinnacle calculation and measurement for the IMRT H&N delivery (single irradiation, number 2) 
 
 
2.3.3.5 Delivery of the SBRT thorax phantom plan: Point dose comparisons 
The results of the point dose comparisons are shown for each TLD measurement 
location in Table 6. Two TLD capsules were located within the center of the target, two TLD 
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capsules within the heart and two TLD capsules within the spinal cord critical structures.  
Included in the table are the average dose measurements and the percent standard deviations 
from the three repeated irradiations.  The comparisons of the target and the critical structures 
between the DPM calculation and measurement and between the Pinnacle calculation and 
measurement were expressed as a ratio.   
 
Point 
dose 
local 
TLD measurement DPM calculation 
Pinnacle calculation 
(reference) 
Avg. 
(cGy) 
% std. 
dev. 
Avg. 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Avg 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Target 
Sup 
774 0.6 783 0.3 1.012 784 0.1 1.013 
Target 
Inf 
769 0.4 780 0.5 1.014 781 0.1 1.015 
Target 
Average 
    1.013   1.014 
Cord 71 0.5 78 1.4 1.089 75 0.1 1.046 
Heart 134 0.7 137 1.7 1.022 132 2.0 0.988 
Table 6 Point dose comparisons of the SBRT thoracic phantom.  The measured dose is the 
average dose from the three repeated irradiations.  Calculated results are from DPM.  The 
Pinnacle calculation is provided for reference.  
 
The agreement between the DPM calculation and measurement for the target on 
average was 1.013.  It is noted that the Pinnacle calculation estimated the point dose to the 
target similar to the DPM calculation so that the ratio between the calculation and measurement 
was 1.014.  While the DPM calculated dose for the heart agreed with measurement (1.022), the 
ratio of the calculated dose to the measured dose to the spinal cord was 1.089.  The cord dose 
was very low.  While the repeatability of the dose was less than 1%, the uncertainty in the dose 
is not known at these low levels.  It was no less than the known uncertainty of 3% for the 
calibration standard dose.  The calibration standard dose was more than four times the 
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benchmark cord dose.  Included in the measurement uncertainty was the phantom setup.  Any 
translational error in the setup would be compounded with the radial distance from the 
isocenter.  The spinal cord was distal to the target at isocenter and would suffer the greatest 
error given such a setup error.  For the calculation, the estimate of uncertainty for the standard 
error of the mean in the voxels that circumscribe the location of the TLD in the spinal cord was 
2.6%.  This was higher than the reported uncertainty because of the fewer number of histories 
reported in the low dose region.  Although this uncertainty does not completely justify the 
overestimation of the DPM calculation, other sources for error include the uncertainty of the 
scatter dose from the extra-focal model as discussed in section 2.3.2.3, the penumbra effect 
from the finite primary source, and the MLC model that defined the leaf transmission factor, 
interleaf leakage, and rounded leaf end. 
The results in Table 7 present the range and average of the ratios between the source 
model and Pinnacle calculations and the measurement for the target and critical structures for 
all TLD locations and all repeated irradiations and not as an average of the repeated irradiations 
as was the data contained in Table 6.  The calculation was 1.0% to 1.8% higher than the 
measurement standard for the target when all TLD locations are compared to the calculation 
locations individually.   
Target Heart Cord Target Heart Cord
high 1.019 1.030 1.095 1.019 0.996 1.051
low 1.008 1.016 1.084 1.009 0.981 1.041
avg 1.013 1.022 1.089 1.014 0.988 1.046
DPM calculation to measurement Pinnacle calculation to measurement
 
Table 7 SBRT lung plan:  The range and average calculation to measurement ratio of the point 
doses for the target, cord, and heart for DPM and Pinnacle. The data is for each TLD location 
from each repeated irradiations. 
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The benchmark evaluation was strictly between the validated source model and 
measurement.  The Pinnacle comparison with the measurement is shown only for reference and 
is representative of the comparison one might find between the source model calculation and a 
state of the art planning system. 
 
2.3.3.6 Delivery of the SBRT thorax phantom plan: Dose profile and gamma map 
comparisons 
Dose profiles along all three major planes are shown in Figure 2.26, Figure 2.27, and 
Figure 2.28.  The figures reported the results from a single irradiation.  As were the results of 
the comparison between the calculation and measurement of the homogeneous, highly 
modulated head and neck plan, the results for the SBRT lung plan were very good.  The 
calculated and measured dose from the lateral, anterior-posterior, and superior-inferior profiles 
agreed in the PTV and penumbra regions, but the lower dose regions showed the calculation 
was slightly overestimating as quantified by the gamma map results.     
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Figure 2.26 SBRT lung delivery single irradiation (number 1): lateral dose profile. 
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Figure 2.27 SBRT lung delivery single irradiation (number 1): A-P dose profile. 
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Figure 2.28 SBRT lung delivery single irradiation (number 1): S-I dose profile. 
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The gamma maps at a test criterion of 3%/2 mm are shown in Figure 2.29, Figure 2.30, 
and Figure 2.31.  The maps reported the results from a single irradiation.  The gamma map of 
the axial plane shows a small disagreement in the entrance dose from one of the beams 
positioned left lateral and posterior of the target,.  Another region of a different beam’s entrance 
dose and an opposing beam’s exit dose, another small disagreement existed.  Regardless, the 
SBRT lung plan had good agreement overall where 94% of the calculated data met the criterion 
of 3%/2 mm.  The DPM dose calculation was able to accurately predict the dose from small 
fields in a low density anthropomorphic phantom.  Gamma maps at the criteria levels of 3%/2 
mm and 5%/3 mm and dose profiles for all three repeated irradiations are presented in the 
Appendix, Chapter 6.   
 
Figure 2.29 SBRT lung delivery single irradiation (number 1): Axial plane, gamma map tested 
to 3%/2 mm criteria, where 90% of the data passed.  Scale is 1 mm = 0.8 mm. Circle outline 
represents the location of the PTV. 
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Figure 2.30 SBRT lung delivery single irradiation (number 1): Sagittal plane, gamma map 
tested to 3%/2 mm criteria, where 95% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
 
 
 
 
Figure 2.31 SBRT lung delivery single irradiation (number 1): Coronal plane, gamma map 
tested to 3%/2 mm criteria, where 93% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
 
 
For reference, the Pinnacle calculation was compared to the same measured data and is 
shown in Figure 2.32.  The results were exceptional throughout the all major planes, including 
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the low dose regions where the DPM calculation was slightly higher.  Note the more abrupt 
field edges from the open beams and the dose pattern created in the regions of intersecting 
beams.  This may be due to the larger dose grid used to perform the Pinnacle calculation (0.4 
cm versus 0.2 cm for DPM).  Or, this may be a result of applying dose kernels or a smoothing 
function across a homogeneous region in contrast to Monte Carlo where the particle history was 
tracked explicitly. 
 
 
  
a) Axial: 3%/2 mm, 93% pass; scale 1mm = 
0.82 mm 
b) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
c) Sagittal: 3%/2 mm, 97% pass; scale 1 mm = 
0.65 mm 
d) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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e) Coronal: 3%/2 mm, 96% pass; scale 1 mm = 
0.65 mm 
f) Coronal: 5%/3 mm, 99% pass; scale 1 mm = 
0.65 mm 
   
e) Lateral profile f) Anterior to posterior profile g) Superior to inferior profile 
Figure 2.32 Gamma map and dose profile comparisons between the Pinnacle calculation and 
measurement for the SBRT lung delivery (single irradiation, number 1) 
 
 
2.3.3.7 Delivery of the IMRT thorax phantom plan: Point dose comparisons 
The results of the point dose comparisons are shown for each TLD measurement 
location in Table 8. As in the SBRT lung case, two TLD capsules were located within the 
center of the target, two TLD capsules within the heart and two TLD capsules within the spinal 
cord critical structures.  Included in the table are the average dose measurements and the 
percent standard deviations from the three repeated irradiations.  The comparisons of the target 
and the critical structures between the DPM calculation and measurement, and between the 
Pinnacle calculation and measurement were expressed as a ratio.   
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Point 
dose 
local 
TLD measurement DPM calculation 
Pinnacle calculation 
(reference) 
Avg. 
(cGy) 
% std. 
dev. 
Avg. 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Avg 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Target 
Sup 
6523 0.4 6697 1.1 1.024 6656 0.2 1.027 
Target 
Inf 
6556 0.4 6721 0.7 1.025 6671 0.2 1.018 
Target 
Average 
    1.025   1.019 
Cord 808 0.2 809 1.1 1.001 800 1.2 0.990 
Heart 1097 1.8 1178 2.0 1.074 1153 1.4 1.052 
Table 8 Point dose comparisons of the IMRT thoracic phantom.  The measured dose is the 
average dose from the three repeated irradiations.  Calculated results are from DPM.  The 
Pinnacle calculation is provided for reference. 
 
 
The DPM calculation overestimated the point dose to the target center by 2.6%.  The 
Pinnacle calculation overestimated the point dose to the target by 1.9%.  The DPM and 
Pinnacle calculation tended to agree for estimates of dose to the critical structures.  The DPM 
calculation correctly predicted the dose to the cord and Pinnacle underestimated the dose by 
1.0%.  While both calculations overestimated the dose to the heart, The DPM calculation dose 
estimate overestimated by more than 7% and the Pinnacle calculation overestimated by more 
than 5%.  The repeatability in the measurement of 1.8% and the standard deviation of the DPM 
calculation of 2.0% could account for some of the discrepancy as the TLD heart location was 
within a dose gradient region that changed by more than 30%/cm,  Also the phantom set-up is 
more sensitive in measurement locations where high dose gradients exist.  While the scatter 
dose was a contributor to uncertainty in the source model based approach, the TLD’s close 
proximity to the target was not believed to be a large contributor to the disagreement in the 
TLD location of the heart. 
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The results in Table 9 present the range and average of the ratios between the source 
model and Pinnacle calculations and the measurement for the target and critical structures for 
all TLD locations and all repeated irradiations and not as an average of the repeated irradiations 
as was the data contained in Table 8.  The calculation was 1.9% to 2.9% higher than the 
measurement standard for the target when all TLD locations are compared to the calculation 
locations individually. 
Target Heart Cord Target Heart Cord
high 1.029 1.092 1.004 1.023 1.070 0.992
low 1.019 1.055 1.000 1.015 1.033 0.988
avg 1.025 1.074 1.001 1.019 1.052 0.990
DPM calculation to measurement Pinnacle calculation to measurement
 
Table 9 IMRT lung:  The range and average calculation to measurement ratio of the point doses 
for the target, cord, and heart for DPM and Pinnacle. The data is for each TLD location from 
each repeated irradiations. 
 
 
The benchmark evaluation was strictly between the validated source model and 
measurement.  The Pinnacle comparison with the measurement is shown only for reference and 
is representative of the comparison one might find between the source model calculation and a 
state of the art planning system. 
2.3.3.8 Delivery of the IMRT thorax phantom plan: Dose profile and gamma map 
comparisons 
Dose profiles along all three major planes are shown in Figure 2.33, Figure 2.34, and 
Figure 2.35.  The gamma maps at a test criterion of 3%/2 mm are shown in Figure 2.36, Figure 
2.37, and Figure 2.38.  These figures reported the results from a single irradiation.  Gamma 
maps at the criteria levels of 3%/2 mm and 5%/3 mm and dose profiles for all three repeated 
irradiations are presented in the Appendix, Chapter 6.  The calculated and measured dose from 
the lateral, anterior-posterior, and superior-inferior profiles generally agreed.  However, the 
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dose profile showed in the posterior penumbra region some local dose differences in the range 
of 3% to 5%.   
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Figure 2.33 IMRT lung delivery single irradiation (number 3): lateral dose profile. 
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Figure 2.34 IMRT lung delivery single irradiation (number 3): A-P dose profile. 
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Figure 2.35 IMRT lung delivery single irradiation (number 3): S-I dose profile. 
 
 
The gamma maps also showed small regions of disagreement which typically occurred 
in the penumbra regions.  The penumbra region represented not only the change in the high 
dose region to low dose region, but also the change from the target tissue-like density to the low 
density region of the lung where electronic disequilibrium occurred.  Disagreement may also be 
more likely to occur near the lung and the chest wall for the same reason.  This may explain 
some of the differences between the calculation and measurement seen on the coronal gamma 
map.     
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Figure 2.36 IMRT lung delivery single irradiation (number 3): Axial plane, gamma map tested 
to 3%/2 mm criteria, where 92% of the data passed.  Scale is 1 mm = 0.8 mm. Circle outline 
represents the location of the PTV. 
 
 
Figure 2.37 IMRT lung delivery single irradiation (number 3): Sagittal plane, gamma map 
tested to 3%/2 mm criteria, where 91% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
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Figure 2.38 IMRT lung delivery single irradiation (number 3): Coronal plane, gamma map 
tested to 3%/2 mm criteria, where 84% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
 
 
Figure 2.39 shows the comparison of the Pinnacle calculation and the same measured 
data used in the DPM evaluation.  The results were very similar to the results from the DPM 
Monte Carlo calculation for each dose profile and each gamma map.   
 
  
a) Axial: 3%/2 mm, 82% pass; scale 1mm = 
0.82 mm 
b) Axial: 5%/3 mm, 97% pass; scale 1mm = 
0.82 mm 
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c) Sagittal: 3%/2 mm, 86% pass; scale 1 mm = 
0.65 mm 
d) Sagittal: 5%/3 mm, 98% pass; scale 1 mm = 
0.65 mm 
  
e) Coronal: 3%/2 mm, 83% pass; scale 1 mm = 
0.65 mm 
f) Coronal: 5%/3 mm, 97% pass; scale 1 mm = 
0.65 mm 
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e) Lateral profile f) Anterior to posterior profile g) Superior to inferior profile 
Figure 2.39 Gamma map and dose profile comparisons between the Pinnacle calculation and 
measurement for the IMRT lung delivery (single irradiation, number 2) 
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2.3.3.9 Benchmark summary 
Table 10 shows the overall results of the percentage of the data that met the gamma 
index criteria of 3% of the normalized PTV dose and 2 mm distance to agreement for the 
comparison between the DPM calculation and measurement.  The table shows the average and 
range from the repeated irradiations for each treatment plan. 
 
IMRT H&N SBRT Lung IMRT Lung
average 93 94 87
range 90-98 90-97 81-92
 
Table 10 Varian 6 MV:  The average and range of the percentage of data from meeting criteria 
from the gamma index of 3%/2 mm for repeated irradiations from each treatment plan. 
 
 
A series of progressively more difficult benchmark tests were designed using IMRT 
and SBRT techniques delivered to homogeneous and heterogeneous phantoms.  An IMRT head 
and neck plan was designed and delivered to the RPC homogeneous head and neck phantom 
using 9 coplanar beams and 72 segments.  The results of this first benchmark test showed that 
on average 93% of the data tested met the criteria of 3% or 2 mm.  The range from the axial and 
sagittal dose planes from all three repeated irradiations was 90% to 98%.  In general, 
disagreement was limited to small regions near the primary target edge and was due to the 
beam penumbra that existed in this particular IMRT plan.  Some disagreement also occurred 
was in posterior and inferior region of the primary target.  This region is adjacent to the spinal 
cord critical structure.  The DPM calculation tended to underestimate the high dose gradient.   
A small field irradiation using 9 coplanar beams was designed and delivered to a low 
density heterogeneous medium using the RPC thorax phantom.  The field was defined by a 
static MLC field with an equivalent square of approximately 5 cm
2
.  The results of this second 
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benchmark test showed that on average 94% of the data tested met the criteria of 3% or 2 mm.  
The range from the axial, coronal, and sagittal dose planes from all three repeated irradiations 
was 90% to 97%.  While nearly all data from all of the three major planes intersecting the 
center of the target met the criteria, the point dose measurement in the target showed the 
calculation to overestimate the dose by 1%.  The DPM calculation accurately predicted the dose 
in the penumbra region of the target and tended to slightly overestimate the dose in the low 
dose regions of the lung.   
Combining the more difficult treatment technique of IMRT with the low-density 
heterogeneous media of the thorax phantom, and IMRT lung plan was designed and delivered 
to the same thorax phantom used for the SBRT test.  In this plan four coplanar beams plus one 
non-coplanar beam consisting of 63 segments were used.  The results of this third benchmark 
test showed that on average 87% of the data tested met the criteria of 3% or 2 mm.  The range 
from the axial, coronal, and sagittal dose planes from all three repeated irradiations was 81% to 
92%.  As expected, combining the low density lung material with IMRT provided the greater 
challenge as greater differences between the calculation and measurement were observed.  The 
DPM calculation overestimated the dose by 2.5% in the center of the target.  Disagreement 
tended to occur in the penumbra regions and in the anterior-medial narrowed lung region in 
between the boundary between the target and the water equivalent tissue where the calculation 
overestimated the dose. 
 
2.4 CONCLUSION 
The analytical source model using the Dose Planning Method (DPM) Monte Carlo 
code, was developed and validated within 2% of the maximum dose and 2 mm distance to 
agreement of measurement for the open field sizes between 4 cm x 4 cm and 40 cm x 40 cm.   
The average local percent differences for the central axis and for the off axis at several depths 
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were found to range from 0.2% to 2.0%.  For field sizes 15 cm x 15 cm and below this range 
was 0.2% to 1.4%.   
The first step of the two-step automated commissioning process that relied on the PDD 
and dose profile measured data from the 10 cm x 10 cm field size was able to optimize the 
energy spectrum for the primary isotropic point source and secondary (extra-focal) photon 
sources, the relative fluence from the extra-focal source, and the relative dose contribution from 
the electron contamination source.  The second step of the commissioning process optimized 
the horn-effect so that the calculation could accurately predict the increase in fluence as the off 
angle axis increased.  For this step, the commissioning process used the dose profile measured 
data from the 40 cm x 40 cm field size.  In addition, the extra-focal source model’s energy 
distribution as described by Liu, et al
30
 was implemented without modification.  A correction to 
the output factor for a given field size was designed in response to the change in the fluence 
contribution that occurs with the change in field size from the extra-focal source.  By 
combining these model attributes, an accurate model for the Varian 6 MV photon beam using 
the DPM Monte Carlo method was able to faithfully calculate the basic beam data that 
comprised of open fields from 4 cm x 4 cm to 40 cm x 40 cm. 
The validated source model with the DPM calculation was found to be accurate within 
3% of the normalization dose and 2 mm distance to agreement of measurement under 
increasingly more difficult benchmark conditions of IMRT and SBRT treatment techniques 
delivered to anthropomorphic phantoms where TLD and radiochromic film measurements were 
made.  The accuracy of the source model calculation for the benchmark tests of an IMRT 
treatment delivered to the homogeneous head and neck phantom, a SBRT treatment delivered 
to the heterogeneous thorax phantom, and an IMRT treatment delivered to the heterogeneous 
thorax phantom ranged from 87% to 94% of the data tested at the gamma index of 3%/2mm. 
To achieve the level of accuracy for the benchmark evaluations, an MLC model was 
developed to account for leaf transmission, interleaf leakage, and the rounded leaf ends.  In 
  68 
addition, the implementation of an MLC offset of 0.4 mm to compensate for the finite size of 
the primary source and reproduce the measured penumbra was necessary for the model to meet 
the conditions of the accuracy defined.  In this work we have demonstrated that with the use of 
the DPM Monte Carlo code, an accurate straightforward multiple-source model was developed 
for the Varian 6 MV photon beam using basic beam data. 
  
Chapter 3 Development, Validation, and Benchmark: 
Varian 10 MV 
 
 
3.1 INTRODUCTION 
The detailed Monte Carlo simulation of an accelerator head including the target, 
primary and secondary collimators, flattening filter, ion chamber, jaws, MLC, and even the 
head shielding and structural components provides a high level of accuracy in describing the 
photon and the contaminate electron distributions.  However, the simulation must be repeated 
for every machine type and energy.  Once the simulation is complete, the fluence generated can 
be transported through the patient using the Monte Carlo method.  As an intermediate step, the 
fluence distribution generated from the initial simulation can then be stored in a phase space 
file.  The phase space file contains the energy, position, and momentum of the photons and 
electrons and is located in a plane perpendicular to the central axis downstream from the exit of 
the treatment head.  An advantage to storing the information in the phase space file is that the 
Monte Carlo transport can be sped up since the transport from the head to the phase space file 
does not need to be repeated.  Further, an analytical model can be used to describe the fluence 
information, thereby replacing the phase space file and eliminating the need to maintain the 
information contained in the file.   
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An alternative to the full simulation method or to the analytical model representation of 
the fluence distribution contained within the simulated phase space file is the use of a virtual 
source model.  The aim of this work was to develop a virtual source model using a multi-source 
model approach to represent the fluence distribution of electrons and photons coming from the 
accelerator head.  The fluence engine is then used to start the Monte Carlo transport of the 
particle histories through the patient.  Multi-source models have long been used in the 
development of early dose calculation algorithms commonly referred to as the pencil beam and 
convolution algorithms.
30,55-60
  One distinct advantage of this approach is the versatility to adapt 
the model to other linear accelerators and other energies, which was the ultimate goal of this 
project. 
The multi-source model developed in this work comprised of a primary source, extra-
focal source, and a source for electron contamination.
26
  The model relied on the Dose Planning 
Method (DPM) Monte Carlo code as the dose calculation algorithm.  The primary source 
described the photons generated at the target.  The extra-focal source was a ‘lumped’ source 
used to describe the remaining photons in the treatment head.  Therefore, the extra-focal 
photons were predominantly generated and scattered photons from the flattening filter, but also 
included photons from the primary collimator, jaws, monitor chamber, etc.
30
  An electron 
contamination source was used to describe electrons that were generated within the treatment 
head from high energy interactions with photons.
31
 
As mentioned above, an advantage of the parameterized source model approach used to 
describe a beam delivery system was its adaptability to characterize other machines and other 
energies.  As an extension of the Varian 6 MV photon beam source model described in Chapter 
2, the Varian 10 MV photon beam source model was reoptimized for the higher energy since 
the components of the Varian accelerator head remained largely the same.  The design of the 
flattening filter for the 10 MV photon beam was different from the Varian 6 MV photon beam.  
This difference was represented by unique parameters that were used to describe the 
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exponential nature of the distribution of photons emanating from a disk at the physical location 
of the flattening filter along the central axis beam line.
30
  While the Varian 6 MV photon beam 
did not include a source for electron contamination because of its small contribution that fell 
below a predetermined limit of 0.5%, electron contamination was modeled for the Varian 10 
MV photon beam.  In addition, the model also accounts for fluence and off-axis energy
27
 effects 
due to the decreasing thickness of the flattening filter from the center to the outer edge.  Known 
as the horn-effect, the fluence increases as the off-axis angle increases; and in conjunction, 
known as off-axis softening, the average energy decreases.  
Modifications to the model that were made to the Varian 6 MV photon beam were 
included in the Varian 10 MV in order to maintain consistency and versatility.  These 
modifications were detailed in Chapter 2 and include an output correction as a function of the 
field size, an MLC offset based on the finite size of the primary source, and the application of a 
blurring function to spread the dose under each MLC leaf tip.  This work presents those 
modifications, details the development effort to modify the fluence from the electron 
contamination source, and reports the results of the validation and benchmark testing of the 
Varian 10 MV photon beam source model with the DPM dose calculation engine.  The 
validation testing compared the DPM source model calculation to the measurement of the 
percent depth dose (PDD) and the dose profiles for open fields.  The benchmark testing 
compared the calculation to measurement using IMRT and SBRT techniques in homogeneous 
and heterogeneous media.   
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3.2 MATERIAL AND METHODS 
3.2.1 Source Model 
3.2.1.1 Source model overview 
Because the source model is generic, much of the methodology remained the same as 
detailed in Section 2.2.  While every aspect and component of the model will be discussed 
herein, the details of the methodology need not be repeated.  One feature unique to the Varian 
10 MV photon beam and source models whose energy is greater than 6 MV was the inclusion 
of the electron contamination model.  Therefore, the electron contamination model will be 
described in detail.   
The dose calculations were performed on the Hewlett Packard ProLiant DL585 G5 
Server with 16 AMD Opteron™ processors and 32GB of RAM.  Each simulation used 10 
million particles per square centimeter beamlet.  The calculations applied low energy electron 
and photon cutoffs of 200 and 50 keV, respectively.  As discussed in the introduction, the 
source model approach facilitated the extension of the model to include other energies.  This 
was achieved, in part, by determining a new set of optimized parameters using the same two-
step automated commissioning process that was described in Section 2.2.1.2.  The remaining 
parts of the model necessary for the validation of the basic beam data were developed for the 
Varian 10 MV photon beam by determining the relationship between the change in photon 
fluence from the extra-focal source and the change in electron fluence from the electron 
contamination source with respect to changes in the field size.  The correction methodology for 
the change in photon fluence was the same as that described in Section 2.2.1.5 where a 
hyperbolic function was fit to the calculated output factor in order to account for the effect of 
head and phantom scatter changes with field size.  The correction for the change in electron 
contamination is detailed in Section 3.2.1.3, below.  The analytical functions from the literature 
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that describe the off-axis softening
27
, the extra-focal fluence distribution
30
, and the electron 
contamination source
31
 where implemented directly and without change. 
For the benchmark testing, the size of the primary source was compensated for by 
applying the same 0.4 mm MLC leaf offset that was modeled for the Varian 6 MV photon 
beam.  The literature has shown the source size is essentially the same regardless of energy.
39-42
  
The amount of leaf transmission, interleaf leakage, and transmission through the round leaf 
ends was determined for MLC model.   
3.2.1.2 Source model commissioning 
For the first step of the two-step commissioning process, energy bins of 0.25 MeV were 
defined from which the DPM dose calculation algorithm calculated dose for each bin using the 
primary source from 0.25 MeV to 12 MeV and using the extra-focal source from 0.25 MeV to 6 
MeV.  For these calculations a 10 cm x 10 cm field was used.  The simulated water phantom 
had dimensions of 50 cm x 50 cm x 50 cm.  The energy spectrum bin weightings, relative 
photon fluence from the extra-focal source, relative fluence from the electron contamination 
source, and the chamber volume effect from the use of an ion chamber used to measure the 
dose profile were optimized until the calculated and measured PDD and dose profiles were in 
agreement.  Seven parameters were determined in order to satisfy the first step of the 
commissioning process. 
For the second step of the commissioning process, the horn-effect influence was 
modeled for the 10 MV photon beam.  Coefficients from a piecewise linear function which was 
used to represent the increase in fluence as a function of an increase in the off-axis angle were 
optimized until the calculated dose profile was in agreement with the measured dose profile of 
a 40 cm x 40 cm open field where the profiles were taken at the depth of maximum dose. 
A final conversion factor was determined by normalizing to an integral dose defined by 
the area under the curve from the measured PDD between the depths of 5 cm to 15 cm for the 
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10 cm x 10 cm open field.
32
  The final conversion factor that was applied to the commissioned 
source model to convert energy per photon to dose.  The factor was applied to all dose 
calculations which included the validation testing, benchmark testing, and any patient 
calculations. 
3.2.1.3 Electron contamination contribution 
Similar in concept to that described in Section 2.2.1.5 for the correction for the 
machine output due to changes in the photon fluence with the field size, a second-order 
hyperbolic equation with three constants described the change in the electron contamination 
contribution
61,62
 as a function of field size to better model the effect that head scatter had on the 
build-up region and depth of maximum dose.  The correction was applied to the three-
dimensional (3D) dose matrix following the dose calculation. 
 
3.2.2 Validation testing 
The validation of the Varian 10 MV photon beam was performed by comparing 
calculated values to the measured values of the basic beam data.  The basic beam data consisted 
of the percent depth dose and the dose profiles at several depths from several field sizes.  
Validation testing used the Varian ‘Gold’ data.  This dataset was chosen over the institution’s 
dataset because it was more complete.  The depths of the dose profile comparisons were 2.4 
cm, 5 cm, 10 cm, and 20 cm in a water phantom.   The field sizes included 4 cm x 4 cm, 6 cm x 
6 cm, 10 cm x 10 cm, 15 cm x 15 cm, 20 cm x 20 cm, 30 cm x 30 cm, and 40 cm x 40 cm.   
The measured values were made using an ion chamber, but it was not clear what type.  
Since it was an ion chamber, it did suffer from volume effects which cause some degree of 
artificially producing a wider penumbra when the dose profile would have been measured.  A 
Gaussian convolution was applied to the calculated dose data for all profile comparisons in 
order to perform a realistic comparison to the measured data.
33
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The calculated data for the Varian 10 MV photon beam was extracted in the same 
manner as the data for the Varian 6 MV photon beam (Section 2.2.3).  Namely, the resolution 
of the calculated data was 0.2 cm (cross-plane) x 0.3 cm (in-plane) x 0.2 cm (depth).  The depth 
of 0 cm was defined along the central axis of the beam where the contoured region that defined 
the surface of the simulated water phantom existed.  The simulated water phantom had 
dimensions of 50 cm x 50 cm x 50 cm. 
The validation test conditions remained unchanged for the 10 MV beam.  The accuracy 
of the calculated data compared to the measured data (PDDs and dose profiles) for field sizes 
from 4 x 4 cm
2
 to 40 x 40 cm
2
 was tested to a gamma criterion of 2% of the maximum dose and 
2 mm distance to agreement.  In addition, local dose differences were studied at depths beyond 
dmax and in the high dose regions of the dose profiles.  The high dose region within a dose 
profile at a specific depth was defined by the dose greater than or equal to 80% of the dose at 
the central axis.
47
  The distance-to-agreement for the location of the calculated dmax relative to 
the measured dmax was also evaluated.   
 
3.2.3 Benchmark testing 
The same type of RPC anthropomorphic phantoms were used in the benchmarking of 
the validated Varian 10 MV photon beam source model.  The approach was the same in terms 
of increased difficulty of the treatment within the media.  Therefore, a combination of IMRT 
and SBRT techniques were used with the homogeneous head and neck phantom (Figure 2.4(a)) 
and the thorax phantom (Figure 2.4(b)).  The head and heck phantom for this study was of the 
same design except the locations for the primary target with critical structure and the secondary 
target were switched as shown in the images in Figure 3.1.  The same thorax phantom was used 
in all studies. 
 
  75 
  
Figure 3.1 CT images of head and neck plans used for benchmark testing.  Left image used 
with Varian 6 MV model.  Right image used for Varian 10 MV image. Viewed I to S. 
 
 
The RPC’s anthropomorphic IMRT head and neck phantom was used to test a highly 
modulated delivery of nine coplanar beams which comprised of 72 segments.  The RPC’s 
anthropomorphic thorax phantom was used to test a nine beam SBRT plan and a five beam, 39-
segment non-coplanar IMRT plan.  The IMRT head and neck plan and SBRT lung plan were 
designed using the credentialing guidelines and irradiation instructions employed by the 
Radiation Therapy Oncology Group (RTOG) to credential institutions for participation in 
specific advanced technology protocols.  Each plan was delivered three times to evaluate the 
repeatability.   
The resolution of the DPM calculation was based on the size of the CT voxel (0.195 cm 
by 0.195 cm by 0.25 cm).  The accuracy of the DPM calculation was determined by comparing 
point doses, dose profiles, and 2D gamma maps to the measured data. 
3.2.3.1 Point dose comparisons 
Point dose comparisons were made between the calculated data and measured TLD 
data.  The TLDs were located in the target and critical structure locations from each phantom.  
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The measured point doses were defined by the small volume of TLD powder inside the capsule 
while the respective calculated point doses were derived from the small regions of interest 
contoured from the CT scan.  
3.2.3.2 Dose profile comparisons 
 Dose profiles along the major planes intersecting the center of the targets were 
evaluated between the calculated and measured film values.  The profiles were used in 
conjunction with the more quantitative point dose comparisons and gamma maps to discuss 
how well the calculation predicted the dose. 
3.2.3.3 Gamma map comparisons 
 
2D dose distributions between the calculation and measurement were evaluated using 
the gamma index method
48
 where quantitative results were recorded and used to test the 
hypothesis.  The gamma criterion remained the same for the Varian 10 MV photon beam as it 
was for the Varian 6 MV photon beam.  The gamma criterion was 3% of the target TLD dose 
and 2 mm distance to agreement.  The regions where the gamma maps have no measured dose 
because of the non-rectangular shape of the film were included in the initial gamma analysis, 
but a subsequent estimate of the data in those regions allowed for a correction to be made to the 
final results. 
3.2.3.4 Treatment plans 
All treatment plans were planned using the Pinnacle treatment planning system 
(version 7.6c or higher) (Philips Medical Systems, Andover, MA).  The dose prescription and 
dose constraints were met based on the calculated dose using Pinnacle’s collapsed cone 
convolution algorithm.   
The summary of the prescription and constraints for each treatment plan is listed below. 
The IMRT head and neck plan: 
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o The PTV was constrained to the gross tumor volume (GTV).   
o At least 95% of the primary planning target volume (PTV) received 6.6Gy (prescribed 
primary dose). 
o Less than 1% of the primary PTV received less that 93% of the prescribed dose.   
o At least 95% of the secondary PTV received 5.4 Gy (prescribed secondary dose). 
o Less than 1% of the secondary PTV received less than 93% of the prescribed dose.  
o The organ at risk received less than 4.5 Gy.   
o The dose to the normal tissue received no more than 7.3 Gy.   
The SBRT lung plan: 
o The PTV was the GTV plus 0.5 cm in the axial plane and plus 1 cm in the longitudinal 
plane.   
o At least 95% of the PTV received 6 Gy  
o At least 99% of the PTV received 5.4 Gy.   
o The maximum dose received at 2 cm and beyond from the PTV was no more than 3.5 
Gy.   
o The dose to the PTV was within 60% and 90% of the maximum dose.   
o The prescription isodose volume to PTV ratio was less than 1.2  
o The ratio of 50% of the prescribed isodose volume to PTV was less than 3.6. 
The IMRT lung plan: 
o The PTV was the GTV plus a 1 cm margin.   
o At least 95% of the PTV received 66 Gy.   
o The maximum dose prescribed to the spinal cord was 45 Gy.   
o No more than 40% of the total lung was to receive more than 20 Gy.   
o The dose to the entire heart was not to exceed 40 Gy  
o No more than 50% of the heart was to receive more than 50 Gy.   
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o Note:  EBT radiochromic film is sensitive in the range of 6 Gy, therefore the delivery 
was limited to 1 fraction and the prescription dose was adjusted accordingly. 
3.3 RESULTS AND DISCUSSION 
3.3.1 Source model 
3.3.1.1 Source model commissioning parameters 
The seven model parameters that described the photon energy spectra, fluence 
contributions, and the penumbra measurement effect from the ion chamber for the first step of 
the commissioning process for the Varian 10 MV photon beam are shown in Table 1.  The first 
three parameters, , , and , defined the spectrum shape, relative peak energy location, and 
relative scale, respectively, of the fatigue life distribution function.   
Parameter Value 
Fatigue-Life distribution shape parameter,  0.8897 
Fatigue-Life distribution location parameter,  -0.0160 
Fatigue-Life distribution scale parameter,  3.92 
Primary spectrum to extra-focal spectrum reduction scale factor 2.8 
Extra-focal fluence relative to the primary fluence 0.23 
Electron contamination contribution (relative to the primary photon 
contribution) 
0.005 
Standard deviation of Gaussian used to convolve the MC dose profile to 
match the measured dose profile during the validation process 
1.2 
Table 11 Parameters of the commissioned source model for spectra, fluence, and profile 
penumbra measurement effect. 
 
 
A plot of the energy spectrum compared to the energy spectrum computed using the 
commonly used BEAM code
29
 for simulating radiation transport in accelerators is shown in 
Figure 3.2.  The commissioned source model spectrum appears representative of the BEAM 
spectrum.  The source model spectrum has more low energy photons and more high energy 
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photons, but this spectrum proved to be an adequate representation of the photon beam based 
on the validation results.  The extra-focal energy spectrum was scaled in energy by a factor of 
2.8.  The relative fluence of the extra-focal source was 23% of the primary source fluence.  This 
is in comparison to 13% for the Varian 6 MV photon beam.  Liu, et al reported the relative 
fluence contribution to be just over 18% of which nearly 1% was attributed to the jaws from an 
open field size of 40 cm x 40 cm.  The dose contribution from the electron contamination 
source was one-half percent (0.5%) of the primary dose.  The standard deviation of the 
Gaussian function used for the dose smearing convolution was 1.2 mm.  This was the same 
value determined in the Varian 6 MV optimization process where the ion chamber was know to 
have an internal volume of 0.04 cm
3
. 
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Figure 3.2 Varian 10 MV spectrum:  Commissioned source model compared to BEAM 
spectrum
29
  
 
 
The results of the second step of the commissioning process are shown in Table 12.  
The horn-effect coefficients of the piecewise linear function are shown as increases in the 
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fluence weighting as a function of the cosine of the off-axis angle.  The horn-effect coefficients 
for the Varian 10 MV model were similar to those reported for the Varian 6 MV model in 
Section Table 2. 
 
 
Cosine(off-axis angle) Fluence weight increase 
1.00000 1 
0.99970 1.310 
0.99879 1.062 
0.99728 1.098 
0.99518 1.13 
0.99250 1.17 
0.98926 1.20 
0.98546 1.24 
0.98113 1.26 
0.97630 1.28 
0.97098 1.30 
0.96277 1.31 
Table 12 Coefficients of a piecewise linear function to describe the increase of fluence as the 
off-axis angle increases (horn-effect) 
 
Following the completion of the two-step commissioning process, the final conversion 
factor that was applied to convert energy per photon to dose in centigray was 0.142368.  This 
factor was applied to every dose calculation performed for the Varian 10 MV source model. 
3.3.1.2 Fluence map, primary source size, and machine output correction 
The Varian 10 MV photon beam applied a transmission of 1% through the bulk 
thickness of the MLC leaves.  This was the same amount of transmission as that applied to the 
Varian 6 MV MLC model.  Even with the higher average energy, the MLC transmission factor 
did not change.  It is worth noting that the Pinnacle model at M.D. Anderson Cancer center uses 
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nearly the same value for the transmission factor for the 6 MV model (1.6%) versus the 18 MV 
model (1.8%).  The interleaf leakage was an additional 1% of the monitor units given for the 
particular segment.  The interleaf leakage was also the same for the 10 MV model as it was for 
the 6 MV model.  The resolution of the fluence map was 1 mm by 1 mm. 
The offset of the MLC leaf positions, xpen, which compensated for the absence of a 
finite primary source size, was fixed at 0.4 mm and considered independent of energy based on 
published reports.
39-42
  The offset amount resulted in a source diameter of 0.84 mm FWHM 
based on the relationship of the source-to-MLC distance and the source-to-axis distance.    
Figure 3.3 shows the relationship between the output factor and the field size for the 
calculated and measured data.  A hyperbolic equation was determined to correct the calculated 
output factors.  This equation, 
1.85
1.10
8.89
y
x
, where y is the output correction and x is 
the field size was necessary to maintain the proper predicted machine output which had been a 
deficiency of the model to completely describe the scatter conditions that change as a function 
of field size. 
  82 
0.90
0.92
0.94
0.96
0.98
1.00
1.02
1.04
1.06
1.08
1.10
1.12
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
Field Size (cm)
O
u
tp
u
t 
fa
c
to
r 
(d
m
a
x
)
Measured Output
Output correction
Calculated output,
corrected
Output correction = 1.10 - 1.85/(8.89 + Field Size)
 
Figure 3.3 Output factor at dmax versus field size for the measured, calculated and corrected 
output.  A hyperbola curve was determined to correct the calculated values. 
 
3.3.1.3 Electron contamination contribution versus field size 
Figure 3.4 shows the relationship between the electron contamination dose relative to 
the dose from the primary source and the field size.  A hyperbolic equation, 
1.008
0.025
40
y
x
, where y is the electron contamination and x is the field size was 
determined empirically from the build-up region of the percent depth dose curve for the field 
sizes 4 cm x 4 cm and 40 cm x 40 cm.  Recall, that the contribution of electron contamination 
for the 10 cm x 10 cm field size (0.50%) was determined during the first step of the automated 
commissioning process (Table 11).   
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Figure 3.4 Plot of the relative electron contamination as a percentage of the dose relative to the 
primary source as a function of field size. 
 
Figure 3.5 and Figure 3.6 show the improvement in the build-up region for the field 
sizes of 4 cm x 4 cm and 40 cm x 40 cm, respectively, due to the correction applied from the 
hyperbolic function.  The improvement in the accuracy of the build-up region for the 4 cm x 4 
cm field size (Figure 3.5 ) was less than for the 40 cm x 40 cm field size (Figure 3.6).  This was 
constrained by the hyperbolic equation, which required no electron contamination contribution 
with the collimator jaws fully closed.  While an improvement in the build-up region for smaller 
field sizes was possible given a different hyperbolic correction equation, an erroneous negative 
electron contamination contribution based on the 0.50% contribution from the commissioned 
10 cm x 10 cm field would have occurred for the fields below the 4 cm x 4 cm field size.  The 
corrected contribution for the 40 cm x 40 cm (Figure 3.6) resulted in a more accurate prediction 
of the build-up region.  Further, the calculation also predicted the correct shift in the dose at 
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maximum depth, dmax, to more shallow depths as the field size increased.  This was expected 
due to the increase in the head scatter with field size.
61
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Figure 3.5 Percent depth dose of 4 cm x 4 cm field size showing build-up region for the 
measured and calculated data sets.  The plot includes the change in the electron contamination 
with field size (corrected) versus a constant contribution, regardless of field size (uncorrected). 
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Figure 3.6 Percent depth dose of 40cm x 40 cm field size showing build-up region for the 
measured and calculated data sets.  The plot includes the change in the electron contamination 
with field size (corrected) versus a constant contribution, regardless of field size (uncorrected). 
 
 
3.3.2 Validation testing 
3.3.2.1 Uncertainty 
The uncertainty of the dose determined from the measurements using an ion chamber 
was estimated to be 1.5% at one standard deviaton.
49
  The standard error of the mean for the 
Monte Carlo simulations was 1% using 10 million particles per square centimeter.
10
 
3.3.2.2 Percent depth dose 
The percent depth dose (PDD) data was compared between the measured data and the 
source model calculated for the field sizes between 4 cm x 4 cm and 40 cm x 40 cm.  While all 
of the PDD comparisons are presented in the appendix (Chapter 6), three fields that represent 
the range of field sizes are presented here.  Those fields are 4 cm x 4cm, 10 cm x 10 cm, and 40 
cm x 40 cm and their data are shown in Figure 3.7, Figure 3.8 and Figure 3.9, respectively. 
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Figure 3.7 Calculated and measured percent depth dose curves at 10 MV for a 4 cm x 4 cm 
field. 
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Figure 3.8 Calculated and measured percent depth dose curves at 10 MV for a 10 cm x 10 cm 
field. 
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Figure 3.9 Calculated and measured percent depth dose curves at 10 MV for a 40 cm x 40 cm 
field. 
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Good agreement existed between the calculated data set and the measured data set 
along the central axis for all of the field sizes tested between 4 cm x 4 cm and 40 cm x 40 cm. 
Beyond dmax, the mean of the local percent difference was within 1.5% for the fields from 4 cm 
x 4 cm (see Figure 3.7) to 40 cm x 40 cm.  The average percentage of those fields tested that 
were within the 2%/2 mm criteria was 98.8%.  The lowest percentage of data meeting the 
criteria occurred within the build-up region of the 6 cm x 6 cm field.  For this field, an average 
of 96.6% met the criterion.     
For the 4 cm x 4 cm field (Figure 3.7), the calculated dmax was 2.5 cm, while the 
measured dmax was 2.6 cm. The calculation did predict the shift of dmax toward shallower depths 
as the field size increased due to the fact of increased scatter with field size from the lower 
energy extra-focal source and the electron contamination source whose dose contribution 
occurs in the build-up region.  The range of the depths for dmax for the field sizes from 4 cm x 4 
cm to 40 cm x 40 cm was 2.5 cm to 2.0 cm for the calculated data and 2.6 cm to 2.0 cm for the 
measured data.  The 10 cm x 10 cm field (Figure 3.8), which was the field that was used to 
commission the source model, the dmax was 2.4 cm for the calculated dose and for the measured 
dose.   
3.3.2.3 Dose profiles 
The dose profile data for the 10 MV photon beam are shown in Figure 3.10, Figure 
3.11, and Figure 3.12 for field sizes of 4 cm x 4, 10 cm x 10 cm, and 40 cm x 40 cm, 
respectively.  The dose profile comparisons for the remaining fields are presented in the 
appendix (Chapter 6).   
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Figure 3.10 Calculated and measured dose profiles at 10 MV from a 4 cm by 4 cm field at 
depths of 2.4 cm, 5 cm, 10 cm, and 20 cm. 
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Figure 3.11 Calculated and measured dose profiles at 10 MV from a 10 cm by 10 cm field at 
depths of 2.4 cm, 5 cm, 10 cm, and 20 cm. 
 
  91 
0 5 10 15 20 25
0
20
40
60
80
100
Off-axis distance (cm)
P
e
rc
e
n
t 
D
o
s
e
 (
%
)
Profiles for FS = 40 x 40 cm2
 
 
Calc 2.4 cm
Meas 2.4 cm
Calc 5 cm
Meas 5 cm
Calc 10 cm
Meas 10 cm
Calc 20 cm
Meas 20 cm
 
Figure 3.12 Calculated and measured dose profiles at 10 MV from a 40 cm by 40 cm field at 
depths of 2.4 cm, 5 cm, 10 cm, and 20 cm. 
 
 
Good agreement existed between the calculation and measurement for all field sizes at 
all depths.  The dose profiles for the field sizes from 4 cm x 4 cm to 15 cm x 15 cm and the 40 
cm x 40 cm filed size met the criteria of 2%/2 mm completely (Table 3).  The remaining two 
field sizes of 20 cm x 20 cm and 30 cm x 30 cm met the 2% or 2 mm criteria at 98%.   
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Field size 
(cm
2
) 
Minimum percentage of data meeting the 
criteria of 2% of dmax or 2 mm DTA 
(%) 
Average percent 
difference (local dose) 
(%) 
4  4 100 0.5 
6  6 100 0.5 
10  10 100 0.8 
15  15 100 1.1 
20  20 98 1.2 
30  30 98 1.2 
40  40 100 0.8 
Figure 3.13 Dose profile agreement between calculated and measured data. Profiles are from 
the depths of 2.4 cm, 5 cm, 10 cm, and 20 cm for each field size. Minimum percentage of the 
data meeting the criteria of 2% of dmax or 2 mm DTA and the percent difference is the average 
of all local percent differences from all of the profiles for a given field.  
 
 
The average local percent difference in the high dose region defined by the measured 
dose values greater than or equal to 80% of the dose at the central axis
47
 was between 0.5% and 
1.2%.  These results are similar to those found for the Varian 6 MV dose profiles.  Some 
disagreement was occurred in the penumbra and low dose regions of the larger fields where 
scatter conditions exhibit their greatest contribution.   
 
3.3.3 Benchmark testing 
3.3.3.1 Uncertainty 
The uncertainty of the dose distribution as determined by the EBT film and TLD at one 
standard deviation was between 2.6% and 3.5%.  This was consistent with a previously 
published report using the same the methodology.
51
  TLD used as an absolute dosimeter helped 
to reduce the variation that can occur between the film calibration process and the actual film 
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used in the phantom at the time of irradiation.  The estimate included the uncertainty of the 
TLD dose,
52
 the film uniformity, the film-to-film variation, and the fit of the sensitometric 
curve.
53
  The TLD uncertainty was included because the film was normalized to the adjacent 
target TLD housed within the phantom.  The estimate of uncertainty, or the standard error of 
the mean, for the simulation was 1% using 10 million particles per square centimeter.
10
   
3.3.3.2 Effect of finite primary source size on benchmark deliveries 
The MLC offset was described in detail in Section 2.3.1.2 and in Figure 2.3.  The MLC 
offset was applied to open each leaf position by 0.4 mm in response to the finite dimension of 
the primary source.  In the study by Rangel and Dunscombe,
54
 they looked at the dosimetric 
impact of MLC position errors in dynamic IMRT deliveries by comparing the equivalent 
uniform dose (EUD) metric to the dose volumes of targets and structures with and without an 
MLC offset.  They chose this metric as a way to relate MLC position changes to the changes in 
dose within a volume.  The EUD describes the dose from a nonuniform dose distribution 
producing the same radiobiological effect as if it was the dose from a uniform dose distribution.  
The increased opening due to the MLC offset resulted in increased head and phantom scatter.  
As expected, an MLC offset in which the leaves are opened resulted in an increase in the EUD 
of an irradiated volume.  In our studies, we found the EUD of the primary PTV in the head and 
neck plan was 3.7% higher, the EUD of the PTV in the SBRT lung plan was 1.1% higher, and 
the EUD of the PTV in the IMRT lung plan was less than 1% higher with an MLC offset of 0.4 
mm.  When compared to the Rangel and Dunscombe results, the IMRT head and neck plan was 
similar.  They reported an average increase of 2.81% in the EUD based on a systematic error of 
a 0.5 mm offset.  The EUD difference with the 0.4 mm offset for the 10 MV IMRT head and 
neck plan was also similar to the 2.4% EUD difference reported in the 6 MV IMRT head and 
neck plan (Section 2.3.3.2).  The differences in the EUD for the unmodulated SBRT lung plan 
and IMRT lung plan were similar to the differences found for the 6 MV lung plans.  These 
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differences, along with the EUD differences for the IMRT head and neck plan, for the Varian 6 
MV and 10 MV source models are shown in Table 13. 
 
   
Varian source model
IMRT                    
head and neck
SBRT lung IMRT lung
6 MV 2.4 1.7 0.0
10 MV 3.7 1.1 0.8
PTV (%)
 
Table 13 Percent differences of the EUD of the MLC offset opening of 0.4 mm (applied to each 
leaf; applied to each segment for IMRT) with respect to no offset (DICOM file with no 
change).  Table compares the EUD for the PTV structure for the Varian 6 MV and 10 MV 
source models. 
 
 
Figure 3.14 shows the frequency histogram of the aperture distances from all three 
benchmark treatment plans.  The aperture distance was defined as the distance between 
opposing leaf ends.  The aperture distances were binned into 10 cm bins.  The histogram 
attempted to explain the differences between treatment plans in terms of the amount of 
modulation and the aperture size.  The IMRT lung plan was not substantially affected by the 0.4 
mm offset.  Consistent with the observation made by Rangel and Dunscombe,
54
 the SBRT and 
IMRT plans had relatively fewer narrow aperture openings compared to the IMRT head and 
neck plan.  In addition, it is clear that an offset of larger proportions would have to increase the 
EUD value because of the increase in machine output given a larger equivalent square field.  
However, since phantom scatter is reduced in the thorax phantom compared to the head and 
neck phantom it is reasonable that the difference in EUD for a small MLC offset for a lung plan 
would be less.       
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Figure 3.14 Frequency histogram of the aperture distances of opposing leaf ends from the 
IMRT head and neck plan, the SBRT lung plan, and the IMRT lung plan. 
 
3.3.3.3 Delivery of the IMRT head and neck phantom plan:  Point dose comparisons 
The results of the point dose comparisons are shown in Table 14 for each TLD 
measurement location.  Four TLD capsules were located within the center of the primary target, 
two TLD capsules within the center of the secondary target and two TLD capsules within the 
spinal cord critical structure.  Included in the table are the average dose measurements and the 
percent standard deviations from the three repeated irradiations.  The comparisons between the 
DPM calculation and measurement and between the Pinnacle calculation and measurement 
were expressed as a ratio for the primary target, the secondary target, and the critical structure. 
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Point 
dose 
local 
TLD measurement DPM calculation 
Pinnacle calculation 
(reference) 
Avg. 
(cGy) 
% std. 
dev. 
Avg. 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Avg 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Pri S-A 696 0.2 675 0.7 0.970 684 0.2 0.983 
Pri S-P 688 0.7 695 0.7 1.010 686 0.2 0.996 
Pri I-A 700 0.1 680 0.7 0.972 686 0.4 0.981 
Pri I-P 696 0.8 692 1.0 0.995 684 0.3 0.983 
Pri Avg     0.987   0.986 
Sec S 547 0.4 537 0.9 0.982 553 0.6 1.011 
Sec I 543 0.3 532 1.5 0.980 552 0.3 1.017 
SecAvg     0.981   1.014 
CS S 185 2.3 163 4.2 0.881 215 4.9 1.166 
CS I 187 2.0 166 4.6 0.889 214 4.9 1.145 
CS Avg     0.885   1.156 
Table 14 Point dose comparisons of the IMRT head and neck phantom.  The measured dose is 
the average dose from the three repeated irradiations.  Calculated results are from DPM.  The 
Pinnacle calculation is provided for reference. Point dose locations are keyed as follows:  Pri = 
primary target; Sec = secondary target; CS = critical structure; S = superior; I = inferior; A = 
anterior; P = posterior. 
 
The ratios of the calculated value to the measured value from the four TLD locations in 
the primary target were averaged so that the over all agreement for the primary target 0.987.  
The range of this averaged value was from 0.970 to 1.010.  For reference, the Pinnacle 
calculation to measurement ratio averaged was 0.986.  For the secondary target, both TLD 
locations showed that on average the calculation was lower than the measurement in the same 
manner as the primary target.  The average of the ratios of the calculated value to the measured 
value was 0.981.  For Pinnacle, the secondary target average of the ratios between the Pinnacle 
calculation and the measurement was 1.014.  The critical structure showed the greatest 
deviation where the average of the ratios of the calculated dose to the measured dose was 0.885.  
In stark contrast, the Pinnacle calculated dose to the measured dose for the critical structure was 
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1.156.   The larger differences between the calculated and measured dose were seen in their 
larger standard deviations (>4%).  This, in large part, was due to the high dose gradient region 
that existed between the critical structure and target. 
The results in Table 15 present the overall range and average of the ratios between the 
source model calculation and the measurement, and between the Pinnacle calculations and the 
measurement for the primary and secondary targets and critical structure for all TLD locations 
and all repeated irradiations and not as an average of the repeated irradiations as was the data 
contained in Table 4. 
Primary 
target
Secondary 
target
Critical 
structure
Primary 
target
Secondary 
target
Critical 
structure
high 1.018 0.985 0.908 1.003 1.020 1.197
low 0.967 0.977 0.868 0.976 1.008 1.125
avg 0.987 0.981 0.885 0.986 1.014 1.156
DPM calculation to measurement Pinnacle calculation to measurement
 
Table 15 IMRT head and neck:  The range and average calculation to TLD measurement ratio 
of the point doses for the primary and secondary targets and critical structure for DPM and 
Pinnacle.  The data is for each TLD location from each repeated irradiations. 
 
 
The benchmark evaluation was strictly between the validated source model and 
measurement.  The Pinnacle comparison with the measurement is shown only for reference and 
is representative of the comparison one might find between the source model calculation and a 
state of the art planning system. 
3.3.3.4 Delivery of the IMRT head and neck phantom plan:  Dose profile and gamma map 
comparisons 
The dose profiles along all three major planes are shown in Figure 3.15, Figure 3.16, 
and Figure 3.17.  The dose profiles show the qualitative agreement between the source model 
DPM calculation and the measured dose and demonstrate the ability of the calculation to 
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predict dose with even small changes in the range of 20 cGy that occurred across short 
distances of about 5 mm.  Good agreement was seen across all dose profiles.   
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Figure 3.15 IMRT H&N delivery single irradiation (number 3): Lateral dose profile. 
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Figure 3.16 IMRT H&N delivery single irradiation (number 3): A-to-P dose profile. 
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Figure 3.17 IMRT H&N delivery single irradiation (number 3): S-to-I dose profile. 
 
Where the dose profiles quantify the amount of dose that was overpredicted or 
underpredicted by the source model calculation along a one dimensional direction, the gamma 
maps quantify the percentage of dose that met the criterion defined by a normalized percentage 
and a distance to agreement.  The calculation and measurement axial and sagittal 2D dose 
planes were tested at a criterion of 3%/2 mm.  The results of these tests are shown as the 
gamma maps in Figure 3.18 and Figure 3.19.  Shown in the figures are the results from a single 
irradiation.  Gamma maps at the criteria levels of 3%/2 mm and 5%/3 mm and dose profiles for 
all three repeated irradiations are presented in the Chapter 6, Appendix.    For the IMRT head 
and neck plan, the percentage of the data meeting the criterion of 3% or 2 mm for the gamma 
maps from the axial and sagittal dose planes intersecting the center of the primary target from 
all three repeated irradiations averaged 94% and ranged from 90% to 97%.  The gamma maps 
showed that in general the calculation predicted the dose within the criteria in the high dose, 
high gradient, and low dose regions within the axial and sagittal planes.  The dose profiles and 
the gamma maps demonstrated that the modeling to describe the penumbra which applied an 
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MLC offset, interleaf leakage, rounded leaf and leaf transmission factors in the highly 
modulated fields of the head and neck plan was correct. 
 
 
Figure 3.18 IMRT H&N delivery single irradiation (number 3): Axial plane, gamma map tested 
to 3%/2 mm criteria, where 99% of the data passed.  Scale is 1 mm = 0.95 mm. Small circle 
outline represents the location of the secondary PTV, large crescent shaped outline represents 
the primary PTV, and the small red circle represents the spinal cord critical structure. 
 
 
Figure 3.19 IMRT H&N delivery single irradiation (number 3): Sagittal plane; gamma map 
tested to 3%/2 mm criteria, where 93% of the data passed.  Scale is 1 mm = 1.3 mm.  Rectangle 
outline represents the location of the primary PTV.  The maroon region in the vertical direction 
is where the film has been cut away to avoid interference with the critical structure region. 
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Figure 3.20 shows the performance of the source model calculation with and without 
the modeling the primary finite source, interleaf leakage, and the effect of the rounded leaf ends 
on transmission.  Note that in addition to an increase in the calculated dose to the primary 
targets, there was an improvement in the shape of the penumbra. 
 
  
a) Gamma map: 3%/2 mm (before) b) Gamma map: 3%/2 mm (after) 
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c) Lateral profile (before) d) Lateral profile (after) 
Figure 3.20 IMRT head and neck:  Gamma maps (a and b) and lateral dose profiles (c and d) 
from the same irradiation, but before (a and c) and after (b and d) changes to the model to 
improve the penumbra. 
 
 
For reference, the Pinnacle calculation was compared to the same measured data and is 
shown in Figure 3.21.  The Pinnacle calculation tended to overpredict and smooth out some of 
the small dose gradients within the primary target.  The small dose gradients were greater than 
the nonuniformity of the film measurement. 
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a) Axial: 3%/2 mm, 82% pass; scale 1mm = 
0.79 mm 
b) Axial: 5%/3 mm, 97% pass; scale 1mm = 
0.79 mm 
  
c) Sagittal: 3%/2 mm, 79% pass; scale 1 mm = 
1.09 mm 
d) 5%/3 mm, 87% pass; scale 1 mm = 1.09 mm 
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e) Lateral profile f) Anterior to posterior profile g) Superior to inferior profile 
Figure 3.21 Gamma map (a thru d) and dose profile (e thru g) comparisons between the 
Pinnacle calculation and measurement for the IMRT H&N delivery (single irradiation, no. 3).  
The gamma map comparisons show results with differing criteria (3%/2 mm vs. 5%/3 mm). 
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3.3.3.5 Delivery of the SBRT thorax phantom:  Point dose comparisons 
The center of the target, the center of the heart, and center of the spinal cord proximal 
to the target each contained two TLD capsules.  The results of the point dose comparisons are 
shown for each TLD measurement location in Table 16.  Included in the table are the average 
dose measurements and the percent standard deviations from the three repeated irradiations.  
The comparisons of the target and the critical structures between the calculations and 
measurement were expressed as a ratio.  The comparisons included both the DPM calculation 
the Pinnacle calculation.   
 
Point 
dose 
local 
TLD measurement DPM calculation 
Pinnacle calculation 
(reference) 
Avg. 
(cGy) 
% std. 
dev. 
Avg. 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Avg 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Target 
Sup 
690 1.1 696 0.2 1.008 684 0.1 0.990 
Target 
Inf 
686 1.9 695 0.3 1.013 682 0.1 0.994 
Target 
Average 
    1.011   0.992 
Cord 68 1.5 70 0.5 1.038 70 0.1 1.028 
Heart 118 0.3 118 1.4 1.005 115 2.4 0.973 
Table 16 Point dose comparisons of the SBRT thoracic phantom.  The measured dose is the 
average dose from the three repeated irradiations.  Calculated results are from DPM.  The 
Pinnacle calculation is provided for reference.  
 
The agreement, expressed as a ratio between the DPM calculation and measurement for 
the target, was on average 1.011.  Similar to the DPM calculation, the Pinnacle calculation 
estimated the point dose to the target within the uncertainty of measurement so that the ratio 
between the Pinnacle calculation and measurement was 0.992 on average.  While the calculated 
dose for the heart agreed well with measurement.  The DPM calculation to measurement ratio 
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for the heart was 1.005.  A greater deviation occurred in the TLD location of the cord where the 
dose was very low and the uncertainty in TLD measurement is greater as the nonlinearity of the 
TLD dose is about four times less than the calibrated standard dose so that the ratio between the 
DPM calculation and measurement was 1.038.  In addition the TLD location was distal to the 
isocenter and would suffer the greatest translational error that would have been due to the 
phantom setup on the treatment couch. 
The results in Table 17 present the range and average of the ratios between the source 
model calculation and the measurement for the target and critical structures for all TLD 
locations and all repeated irradiations, and not as an average of the repeated irradiations as was 
the data contained in Table 16.  The Pinnacle calculation to measurement ratio is also included 
in Table 17.  The source model calculation was to measurement ratio for the target when all 
TLD locations are considered was 1.011 with a range from 0.997 to 1.036.  The narrow range 
of the calculation to measurement ratios for the TLD locations for the each structure showed 
the consistency of the repeated irradiations. 
Target Heart Cord Target Heart Cord
high 1.036 1.008 1.049 1.016 0.976 1.039
low 0.997 1.002 1.027 0.980 0.970 1.017
avg 1.011 1.005 1.038 0.992 0.973 1.028
DPM calculation to measurement Pinnacle calculation to measurement
 
Table 17 SBRT lung plan:  The range and average calculation to measurement ratio of the point 
doses for the target, cord, and heart for DPM and Pinnacle. The data is for each TLD location 
from each repeated irradiations. 
 
The benchmark evaluation was strictly between the validated source model and 
measurement.  The Pinnacle comparison with the measurement is shown only for reference and 
is representative of the comparison one might find between the source model calculation and a 
state of the art planning system. 
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3.3.3.6 Delivery of the SBRT thorax phantom plan:  Dose profile and gamma map 
comparisons 
Dose profiles along all three major planes are shown in Figure 3.22, Figure 3.23, and 
Figure 3.24.  The figures reported the results from a single irradiation.  As were the results of 
the comparison between the calculation and measurement of the homogeneous, highly 
modulated head and neck plan, the results for the SBRT lung plan were very good.  The 
calculated and measured dose from the lateral, anterior-posterior, and superior-inferior profiles 
agreed in the PTV and penumbra regions.  Some small differences up to about 3% were found 
within the PTV.  The variation of the measurement in this region may be, in part, due to the 
film uncertainty as the SBRT plan was not modulated beyond the same static open field with 
nine symmetric beams, therefore a fairly flat dose profile was expected.  The location of the 
target in the medial-lateral direction from the center of the lung may have accounted from some 
of nonuniformity of the dose distribution within the PTV.     
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Figure 3.22 SBRT lung delivery single irradiation (number 1): lateral dose profile. 
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Figure 3.23 SBRT lung delivery single irradiation (number 1): A-P dose profile. 
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Figure 3.24 SBRT lung delivery single irradiation (number 1): S-I dose profile. 
 
 
The gamma maps at a test criterion of 3%/2 mm are shown in Figure 3.25, Figure 3.26, 
and Figure 3.27.  The maps were based on a single irradiation.  The gamma maps in all three 
major planes showed that agreement was very good and met the criterion except for the region 
adjacent in the medial and lateral directions of the target.  This region was near the boundary 
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interface between the lung and chest wall where electronic disequilibrium occurs and requires 
some distance to re-establish equilibrium.  Not accounting for all the scatter conditions within 
the extra-focal source may be the most sensitive to this condition where the boundary condition 
existed at the lung interface.   The SBRT lung plan had good agreement overall where 96% of 
the calculated data met the criterion of 3%/2 mm.  The DPM dose calculation was able to 
accurately predict the dose from small fields in a low density anthropomorphic phantom for the 
Varian 10 MV photon beam.  Gamma maps at the criteria levels of 3%/2 mm and 5%/3 mm 
and dose profiles for all three repeated irradiations are presented in the Appendix, Chapter 6. 
 
Figure 3.25 SBRT lung delivery single irradiation (number 1): Axial plane, gamma map tested 
to 3%/2 mm criteria, where 98% of the data passed.  Scale is 1 mm = 0.8 mm. Circle outline 
represents the location of the PTV. 
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Figure 3.26 SBRT lung delivery single irradiation (number 1): Sagittal plane, gamma map 
tested to 3%/2 mm criteria, where 97% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
 
 
 
 
Figure 3.27 SBRT lung delivery single irradiation (number 1): Coronal plane, gamma map 
tested to 3%/2 mm criteria, where 98% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
 
 
For reference, the Pinnacle calculation was compared to the same measured data and is 
shown in Figure 3.28.  The results were similar to the DPM calculation.  The small amount of 
disagreement tended to occur near the target edge and into the penumbra region of the lung 
material. 
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a) Axial: 3%/2 mm, 98% pass; scale 1mm = 
0.82 mm 
b) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
c) Sagittal: 3%/2 mm, 95% pass; scale 1 mm = 
0.65 mm 
d) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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e) Coronal: 3%/2 mm, 96% pass; scale 1 mm = 
0.65 mm 
f) Coronal: 5%/3 mm, 99% pass; scale 1 mm = 
0.65 mm 
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e) Lateral profile f) Anterior to posterior profile g) Superior to inferior profile 
Figure 3.28 Gamma map and dose profile comparisons between the Pinnacle calculation and 
measurement for the SBRT lung delivery (single irradiation, number 1) 
 
3.3.3.7 Delivery of the IMRT thorax phantom plan:  Point dose comparisons 
The results of the point dose comparisons are shown for each TLD measurement 
location in Table 18. Using the same thorax phantom as that used for the SBRT lung plan, the 
same TLD locations were used.  Namely, two TLD capsules were located within the center of 
the target, two TLD capsules within the heart and two TLD capsules within the spinal cord 
critical structures.  The average dose measurements and the percent standard deviations from 
the three repeated irradiations are also given.  The comparisons of the target and the critical 
structures between the DPM calculation and measurement and comparisons between the 
Pinnacle calculation and measurement were expressed as a ratio. 
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Point 
dose 
local 
TLD measurement DPM calculation 
Pinnacle calculation 
(reference) 
Avg. 
(cGy) 
% std. 
dev. 
Avg. 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Avg 
(cGy) 
% std. 
dev. 
Ratio 
calc/meas 
Target 
Sup 
608 1.9 623 0.6 1.025 624 0.4 1.027 
Target 
Inf 
620 0.6 632 1.0 1.019 628 0.1 1.014 
Target 
Average 
    1.022   1.020 
Cord 53 0.5 51 7.0 0.962 53 4.1 0.994 
Heart 81 0.9 86 5.2 1.062 91 4.8 1.127 
Table 18 Point dose comparisons of the IMRT thoracic phantom.  The measured dose is the 
average dose from the three repeated irradiations.  Calculated results are from DPM.  The 
Pinnacle calculation is provided for reference. 
 
The DPM calculation overestimated the point dose to the target center by an average of 
2.2%.  The Pinnacle calculation overestimated the point dose to the target by an average of 
2.0%.  The standard deviation of the DPM calculation for the critical structures was large from 
5.2% to 7.0%, which was enough to account for the variation in the dose estimations of the 
spinal cord (0.962, calculation to measurement ratio) and heart (1.062, calculation to 
measurement ratio).  The Pinnacle calculation also reported standard deviations to account for 
some of the variation for the ratio of the calculation to measurement of 1.127 for the heart.  
Since both the DPM and Pinnacle reported high standard deviations for the small regions of 
interest of the TLD within the cord and heart, most likely this was due to the dose gradients that 
existed in these regions.  Other sources for error would include the smaller number of histories 
recorded in the voxels distal to the PTV where most of the energy was deposited.  The distal 
regions of cord and heart where the dose is much lower are influenced more by the second and 
third order scatter kernels of the convolution algorithm, which are less accurate. 
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The range and average of the ratios between the source model calculation and the 
measurement, and between the Pinnacle calculation and the measurement for the target and 
critical structures for all TLD locations and all repeated irradiations are shown in Table 19.  
The ratio of the source model calculation to measurement ranged from 1.003 to 1.037 for all the 
TLD locations from all of the repeated irradiations evaluated within the target.   
Target Heart Cord Target Heart Cord
high 1.037 1.072 0.965 1.038 1.139 0.997
low 1.003 1.055 0.956 1.004 1.120 0.988
avg 1.022 1.062 0.962 1.020 1.127 0.994
DPM calculation to measurement Pinnacle calculation to measurement
 
Table 19 IMRT lung:  The range and average calculation to measurement ratio of the point 
doses for the target, cord, and heart for DPM and Pinnacle. The data is for each TLD location 
from each repeated irradiations. 
 
 
The benchmark evaluation was strictly between the validated source model and 
measurement.  The Pinnacle comparison with the measurement is shown only for reference and 
is representative of the comparison one might find between the source model calculation and a 
state of the art planning system. 
3.3.3.8 Delivery of the IMRT thorax phantom plan:  Dose profile and gamma map 
comparisons 
Dose profiles along all three major planes are shown in Figure 2.33, Figure 2.34, and 
Figure 2.35.  The gamma maps at a test criterion of 3%/2 mm are shown in Figure 2.36, Figure 
2.37, and Figure 2.38.  These figures reported the results from a single irradiation.  Gamma 
maps at the criteria levels of 3%/2 mm and 5%/3 mm and dose profiles for all three repeated 
irradiations are presented in the Appendix Chapter 6.  The calculated and measured dose from 
the lateral, anterior-posterior, and superior-inferior profiles generally agreed.  However, the 
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dose profile showed in the posterior penumbra region some local dose differences in the range 
of 3% to 5%. 
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Figure 3.29 IMRT lung delivery single irradiation (number 1): lateral dose profile. 
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Figure 3.30 IMRT lung delivery single irradiation (number 1): A-P dose profile. 
 
  114 
0 10 20 30 40 50 60 70 80 90
200
250
300
350
400
450
500
550
600
650
700
 Distance along line
 D
o
s
e
 V
a
lu
e
Calc
Meas
 
Figure 3.31 IMRT lung delivery single irradiation (number 1): S-I dose profile. 
 
 
The gamma maps also showed small regions of disagreement which typically occurred 
in the penumbra regions.  The penumbra region represented not only the change in the high 
dose region to low dose region, but also the change from the target tissue-like density to the low 
density region of the lung where electronic disequilibrium occurred.  Disagreement may also be 
more likely to occur near the lung and the chest wall for the same reason.  This may explain 
some of the differences between the calculation and measurement seen on the coronal gamma 
map.     
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Figure 3.32 IMRT lung delivery single irradiation (number 1): Axial plane, gamma map tested 
to 3%/2 mm criteria, where 92% of the data passed.  Scale is 1 mm = 0.8 mm. Circle outline 
represents the location of the PTV. 
 
 
Figure 3.33 IMRT lung delivery single irradiation (number 1): Sagittal plane, gamma map 
tested to 3%/2 mm criteria, where 84% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
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Figure 3.34 IMRT lung delivery single irradiation (number 1): Coronal plane, gamma map 
tested to 3%/2 mm criteria, where 86% of the data passed.  Scale is 1 mm = 0.65 mm. 
Elongated circle outline represents the location of the PTV. 
 
 
The comparison of the Pinnacle calculation and the same measured data used in the 
DPM evaluation above is shown in Figure 3.35.  The results were similar to the results from the 
DPM Monte Carlo calculation in terms of disagreement occurring in the penumbra region.   
However, where the DPM calculation overpredicted dose in the penumbra, the Pinnacle 
calculation underpredicted the dose and tended to overestimate the broadening of the 
penumbra.   
  
a) Axial: 3%/2 mm, 90% pass; scale 1mm = 
0.82 mm 
b) Axial: 5%/3 mm, 99% pass; scale 1mm = 
0.82 mm 
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c) Sagittal: 3%/2 mm, 86% pass; scale 1 mm = 
0.65 mm 
d) Sagittal: 5%/3 mm, 98% pass; scale 1 mm = 
0.65 mm 
  
e) Coronal: 3%/2 mm, 72% pass; scale 1 mm = 
0.65 mm 
f) Coronal: 5%/3 mm, 92% pass; scale 1 mm = 
0.65 mm 
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e) Lateral profile f) Anterior to posterior profile g) Superior to inferior profile 
Figure 3.35 Gamma map and dose profile comparisons between the Pinnacle calculation and 
measurement for the IMRT lung delivery (single irradiation, number 1) 
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3.3.3.9 Benchmark summary 
The overall results of the percentage of the data that met the gamma index criteria of 
3% of the normalized PTV dose or 2 mm distance to agreement for the comparison between the 
DPM calculation and measurement is shown in Table 20.  The average and range from the 
repeated irradiations for each treatment plan are included in the data.  The percentage of data 
that met the gamma index criteria for the Varian 6 MV source model are shown in parenthesis 
in Table 20. 
IMRT H&N SBRT Lung IMRT Lung
average 94 (93) 96 (94) 85 (87)
range 90-97 (90-98) 91-98 (90-97) 79-90 (81-92)
 
Table 20 Varian 6 MV and 10 MV:  The average and range of the percentage of data from 
meeting criteria from the gamma index of 3%/2 mm for repeated irradiations from each 
treatment plan.  Values in parenthesis are corresponding numbers for 6 MV results. 
 
The methodology for evaluation of source model energies was designed to be 
consistent.  The plan prescription, constraints, and beam gantry angles were the same for the 
IMRT head and neck plan, SBRT lung plan, and IMRT lung plan.   In addition, the MLC field 
conformed to the same PTV for both energies.  The trend for the percentage of data meeting the 
criteria was the same for the Varian 6 MV and 10 MV source models.  In addition, the range of 
the percentage of data meeting criteria was also similar indicating consistent methodology.  
Benchmark treatment plans were designed at three different levels of difficultly so that the 
source model with the DPM Monte Carlo calculation was thoroughly tested.  The first test was 
an IMRT head and neck plan with a primary and secondary PTV, but delivered to a 
homogeneous phantom.  Next, an SBRT lung plan using a small field with an equivalent square 
of approximately 5 cm
2
 was delivered to a heterogeneous phantom where the target was 
positioned near the anterior medial edge of the low-density lung material.  The final test used 
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the same heterogeneous thorax phantom that was used in the SBRT deliveries, but instead an 
IMRT lung plan was designed including one non-coplanar beam.   
The results of this first benchmark test showed that an average of 94% of the data 
tested met the criteria of 3% or 2 mm.  The range from the axial and sagittal dose planes from 
all three repeated irradiations was 90% to 97%.  In general, disagreement was limited to small 
regions within the primary target edge and was due to the beam penumbra that existed within 
the primary PTV in this IMRT plan.  Even in the steep dose gradient region between the 
adjacent structures of the primary PTV and the spinal cord the agreement was within the 
criteria.  
The results of SBRT lung plan, the second benchmark test, showed that an average of 
96% of the data tested met the criteria of 3% or 2 mm.  The range from the axial, coronal, and 
sagittal dose planes from all three repeated irradiations was 91% to 98.  Nearly all data from all 
of the three major planes intersecting the center of the target met the criteria.  The point dose 
measurement in the target showed the calculation to overestimate the dose by 1%.     
The final benchmark test was the IMRT lung plan.  The results showed that an average 
of 85% of the data tested met the criteria of 3% or 2 mm.  The range from the axial, coronal, 
and sagittal dose planes from all three repeated irradiations was 79% to 90%.  As expected, 
combining the low density lung material with IMRT provided the greater challenge as greater 
differences between the calculation and measurement were observed.  The DPM calculation 
overestimated the dose by 2.2% in the center of the target.  Disagreement occurred in the 
penumbra regions posterior and medial-lateral/anterior of the target.  Since agreement was 
typical in the distal-lateral direction, the regions of disagreement may be due to electronic 
disequilibrium crossing at a boundary and into low-density heterogeneous regions.  In these 
regions, the DPM calculation overestimated the dose.  Another region of disagreement occurred 
in the low dose regions.  Disagreement here may also be due to the heterogeneous boundary 
condition as the DPM calculation overestimated the dose at the lung and chest wall interface. 
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3.4 CONCLUSION 
The analytical source model using the Dose Planning Method (DPM) Monte Carlo 
calculation was developed and validated within 2% of the maximum dose and 2 mm distance to 
agreement of measurement for the open field sizes between 4 cm x 4 cm and 40 cm x 40 cm.   
The average local percent difference for the central axis dose beyond dmax was 1.0% and the 
range was 0.5% to 1.5%.   The average local percent difference for the off-axis dose at several 
different depths and whose dose was greater than or equal to 80% of the dose at the central axis 
dose at depth
47
 was 0.5% to 1.2%.  
The first step of the two-step automated commissioning process that relied on the PDD 
and dose profile measured data from the 10 cm x 10 cm field size was able to optimize the 
energy spectrum for the primary isotropic point source and secondary (extra-focal) photon 
sources, the relative fluence from the extra-focal source, and the relative dose contribution from 
the electron contamination source.  The second step of the commissioning process optimized 
the horn-effect so that the calculation could accurately predict the increase in fluence as the off 
angle axis increased.  For this step, the commissioning process used the dose profile measured 
data from the 40 cm x 40 cm field size.  In addition, the extra-focal source model’s energy 
distribution as described by Liu, et al
30
 was implemented without modification.  A correction to 
the output factor for a given field size was designed in response to the change in the fluence 
contribution that occurs with the change in field size from the extra-focal source.  Similarly, a 
correction to account for the change in electron contamination with a change in the field size 
was designed to improve the build-up region and the depth of maximum dose.  By combining 
these model attributes to represent the output of the linear accelerator, an accurate model for the 
Varian 10 MV photon beam using the DPM Monte Carlo method was able to faithfully 
calculate the basic beam data that comprised of open fields from 4 cm x 4 cm to 40 cm x 40 cm. 
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The validated source model with the DPM calculation was found to be accurate within 
3% of the normalization dose and 2 mm distance to agreement of measurement under 
progressively more difficult benchmark conditions of IMRT and SBRT treatment techniques 
delivered to anthropomorphic phantoms where TLD and radiochromic film measurements were 
made.  The accuracy of the source model calculation for the benchmark tests of an IMRT 
treatment delivered to the homogeneous head and neck phantom, a SBRT treatment delivered 
to the heterogeneous thorax phantom, and an IMRT treatment delivered to the heterogeneous 
thorax phantom ranged from 85% to 96% of the data tested at the gamma index of 3%/2mm. 
To achieve the level of accuracy for the benchmark evaluations, an MLC model was 
developed to account for leaf transmission, interleaf leakage, and the rounded leaf ends.  In 
addition, the implementation of an MLC offset of 0.4 mm to compensate for the finite size of 
the primary source and reproduce the measured penumbra was necessary for the model to meet 
the conditions of the accuracy defined.  In this work we have demonstrated that with the use of 
the DPM Monte Carlo code, an accurate straightforward multiple-source model was developed 
for the Varian 10 MV photon beam using basic beam data. 
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Chapter 4 Patient Dose Comparisons: Varian 6 MV & 10 MV 
 
4.1 INTRODUCTION 
An obviously important quality assurance aspect of a clinical trial in radiotherapy is the 
ability to analyze the results of the advanced treatment being studied.  The analysis is a difficult 
task because of the complexity of disease and the need to organize and track the information 
about a patient’s treatment and follow-up evaluations over a period of time.  A coordinated and 
efficient approach is required to provide a timely response to the treatment outcomes analysis.  
Steady progress of new technologies introduced into the clinic with the emphasis for their 
justification make it critical to ascertain if the patient is benefiting from the proposed advances.  
The Radiation Therapy Oncology Group (RTOG), intimately involved with clinical trials, is 
chartered with the task of evaluating the new methods of delivery with the ultimate goal of 
improving local and regional control, and survival.   
Recent publications have focused on improving the outcome analysis process.
34,63,64
  In 
these publications, the patients are from a single institution and rely on a single dose calculation 
algorithm, thus these variables are already minimized.  Centralizing the patient data is an 
important first step to minimize and control the number of input variables used in the biological 
model.  As part of the outcomes analysis process in clinical trials, dose distributions from the 
enrolled patients are from a multitude of participating institutions via the institution’s dose 
calculation algorithm embedded within their treatment planning system.  When all of the 
patient data from all of the institutions are combined, an outcome analysis assumes the dose 
data are correct.  Participating institutions may use any number of different commercially 
available dose calculation algorithms to predict the patient’s dose distribution.  Additionally, 
each institution is responsible for creating an accurate beam model based on the algorithm.  
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Finally, institutions utilize linear accelerators from several manufactures and when combined 
with the different dose calculation algorithms, another layer of complexity is added.   
One way to eliminate these variables and unify the patient dose distributions is to use a 
single independent dose calculation algorithm, such as the Monte Carlo (MC) method.  
Generally considered the most accurate method to determine dose, it has yet to see widespread 
use in the clinic for photon dose calculations mainly because of the intense amount of 
computational power necessary to perform the calculations.  A drawback for the purposes of an 
independent method for use in clinical trials is that the MC method traditionally relies on 
detailed modeling of the treatment head.  This process would have to be repeated for every 
linear accelerator type and energy and is dependent on the detail of the machine specification.  
Instead, a measurement-driven source model approach, such as the one described in Chapter 2 
and Chapter 3, that applies parameterized analytical functions to describe the energy spectrum 
and distribution of primary and secondary photons and contaminant electrons provides a 
generic standard dose calculation methodology for any source and its resulting output, 
regardless of the type of accelerator.  To date, this source model has been developed, validated, 
and benchmarked for the Varian 6 MV and 10 MV photon beams using the Dose Planning 
Method (DPM) Monte Carlo code as the dose calculation engine. 
The mission of the Radiological Physics Center is to assure the NCI and the 
Cooperative Groups, such as the RTOG, that institutions participating in clinical trials deliver 
prescribed radiation doses that are clinically comparable and consistent. The RPC assists the 
study groups in developing protocols and QA procedures.  Implementing the independent and 
generic source model DPM dose calculation algorithm for use by the RPC will enhance the way 
the clinical trial community performs retrospective dose calculations and outcomes analysis by 
assuring the dose data are correct. 
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4.2 MATERIAL AND METHODS 
4.2.1 Recalculations using DPM 
Source models were developed and validated for the Varian 6 MV and Varian 10 MV 
photon beams.  The DPM code was used to perform the Monte Carlo dose calculations.  The 
details of the source model development and validation were described in Chapter 2 (Varian 6 
MV) and Chapter 3 (Varian 10 MV).  The source model DPM calculation was applied to 
several patient cases.  The purpose was to benchmark a commercial treatment planning 
system’s dose calculation algorithm against the validated and benchmarked independent dose 
calculation tool in an effort to establish a baseline of what might be expected from a 
retrospective calculation study as part of the clinical trial outcomes analysis.  The cases were 
selected from a database of past patient treatments that were previously planned on the Pinnacle 
treatment planning system (TPS) (version 7.6c, or higher) (Philips Medical Systems, Andover, 
MA).  Common treatments that applied IMRT and SBRT to disease sites in water-like and low 
density tissue anatomy were studied.  The test cases included treatments of the prostate, 
abdomen, and lung.  Specifically, the recalculated treatments using the source model DPM 
calculation were: 
 IMRT abdomen, 6 MV, 9 beams, 134 segments 
 IMRT prostate, 10 MV, 9 beams, 93 segments 
 SBRT lung, 6 MV, 7 beams, equivalent field size from 5.2 cm2 to 5.8 cm2 
 IMRT lung, 10 MV, 6 beams, 82 segments 
Additionally, a useful exercise was performed to bridge the benchmarking of the 
independent dose calculation tool using the anthropomorphic phantoms to the recalculation of 
the patient plans.   This exercise compared the DPM calculation to the TPS calculation of the 
phantom plans in the same way the comparisons were made from the patient plans.  These 
analyses are described below. 
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The RTOG CT images and DICOM RT plan were exported from the Pinnacle 
treatment planning system and imported into CERR, the Computational Environment for 
Radiotherapy Research software platform (Washington University, St. Louis, MO), where the 
source model DPM calculations were performed on a Hewlett Packard ProLiant DL585 G5 
Server with 16 AMD Opteron™ processors and 32GB of RAM.  Each plan was simulated with 
10 million photons per square centimeter defined at the isocenter plane so that the standard 
error of the mean was 1% for those voxels whose dose value was at least 50% of the maximum 
dose.  The simulation applied low energy electron and photon cutoffs of 200 and 50 keV, 
respectively.   
4.2.2 Patient plan analysis 
The comparisons for each plan included quantifying the dose in the regions of interest, 
dose volume histograms, and 2D dose distributions that were evaluated using the gamma index 
method.
48
  In addition, the same analysis was performed between Pinnacle and the source 
model DPM calculation for the measurement benchmark cases described in Chapter 2 and 
Chapter 3 that used the RPC head and neck and thorax phantoms.  For the 2D dose distribution 
evaluation, the gamma criteria was 5% of the maximum dose and 3 mm distance to agreement 
to match the criteria applied by the RPC in their QA protocols.  Presently, the gamma analysis 
erroneously considers the data outside the skin contour of the patient and artificially inflates the 
percentage of pixels meeting the criteria.  Therefore, the gamma analysis was only meant to 
show where the regions of agreement and disagreement existed. 
The procedure used to perform the patient IMRT quality assurance (QA) at MD 
Anderson was used on the IMRT head and neck 6 MV anthropomorphic phantom plan.  The 
IMRT QA procedure used an ion chamber (IC) placed into a standard phantom (I’mRT QA 
phantom, IBA Dosimetery America, Bartlett, TN) and located in the GTV where the standard 
deviation of the predicted dose within the volume of the IC was less than one percent as 
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reported by the TPS calculation.  In addition, this procedure was repeated a second time with a 
second location selected for placement of the IC.  The plan was also calculated for the second 
location.  A comparison of the average ratios between the TPS calculation and the IC 
measurement and between the DPM calculation and IC measurement was made.  To perform 
the DPM calculation, the QA phantom material (98% polystyrene, 2% titanium dioxide) was 
specified within the DPM code in order to obtain the material probability cross section data.   
 
4.3 RESULTS 
4.3.1 Dose in region of interest 
Table 21 shows the mean dose from several regions of interest for the patient treatment 
plans studied (prostate, abdomen, and lung), as well as the for the treatment plans delivered 
(head and neck and lung) to the anthropomorphic phantoms.   
Plan Treatment Energy GTV PTV
IMRT abdomen 1.016 1.008 1.033 (kidney)
SBRT lung 1.000 0.984 0.979 (cord)
IMRT prostate 1.000 0.996 0.998 (femur)
IMRT lung N/A 1.008 1.034 (carina)
IMRT head/neck 1.049 N/A 1.198 (cord)
SBRT lung 1.002 0.987 0.977 (heart)
IMRT lung 1.015 1.010 1.014 (heart)
IMRT head/neck 1.019 N/A 1.253 (cord)
SBRT lung 0.990 0.974 0.999 (heart)
IMRT lung 1.008 0.984 1.010 (heart)
phantom
6
10
Critical Structure
patient
6
10
 
Table 21 Ratio of TPS calculation to DPM calculation for mean dose to GTV, PTV, and critical 
structure for patient and phantom plans.  Performance trends are similar as noted by SBRT 
plans 
 
In all cases the difference in the mean dose to the gross target volume (GTV) and to 
planning target volume (PTV) between the calculations was within 2.6% except for the 6 MV 
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IMRT head and neck benchmark phantom plan.  In this case the ratio of TPS calculation to 
DPM calculation was 1.049.  Table 4 presented the results from the benchmark testing of this 
plan which showed the TPS calculation overestimated the dose to the TLD in the center of the 
GTV by 1.043 on average.  In contrast, the DPM calculation underestimated the dose to the 
TLD by 0.983 on average.  To understand the differences between the two calculations, the 
results of the IMRT QA procedure and the selected benchmark results from Table 4 are shown 
in Table 22. 
Comparison ratio Phantom Region Ratio
TPS/DPM H&N mean GTV 1.049
TPS/TLD 1.043
DPM/TLD 0.983
TPS/IC 1.016
DPM/IC 0.987
H&N
point GTV
QA
 
Table 22 Comparison of calculation and measurement in GTV for 6 MV IMRT head and neck 
plan.  Benchmark phantom and IMRT QA phantom included. 
 
It is clear from Table 22 the DPM calculation consistently underpredicted the dose for the 6 
MV IMRT head and neck plan by a small amount (ratios of 0.983 and 0.987) regardless of the 
phantom used.  While the TPS calculation slightly overpredicted the dose in the QA phantom 
(1.016), the overestimation to the benchmark anthropomorphic phantom was much greater 
(1.043).  Relative to the TLD value, it was inferred that the ratio of the TPS to DPM was 1.061.  
This ratio was reasonable for the mean GTV when compared to the ratio between the TPS 
calculation and the DPM calculation of 1.049.  The discrepancy between the anthropomorphic 
phantom and QA phantom used with the TPS calculation could reside within the specific plan 
as the other benchmark testing and patient studies did not exhibit this level of disagreement.  
While the 10 MV IMRT head and neck phantom plan revealed similar discrepancies, the 
disagreement was not the same magnitude.  For this plan, the use of the DPM calculation would 
have provided a better correlation between the phantom plan and the QA plan and may be due 
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to the superior MC physics which included the detailed material specification of both 
phantoms.  The independent dose calculation tool demonstrates the benefit of the MC 
calculation to accurately calculate the dose regardless of the heterogeneities involved. 
4.3.2 Dose distribution analysis 
Dose volume histograms (DVHs), gamma maps, and dose profiles were generated for 
the patient treatment plans studied (prostate, abdomen, and lung), as well as the for the 
treatment plans delivered (head and neck and lung) to the anthropomorphic phantoms.  The 
gamma map analysis method was applied to the patient treatment plans (prostate, abdomen, and 
lung), as well as for the anthropomorphic phantom treatment plans (head and neck and lung) for 
the axial plane in the center of the target for each plan evaluated.  The gamma criteria were 5% 
of the maximum DPM dose and 3 mm distance-to-agreement.  An associated CT scan image is 
provided for each gamma map.  An arbitrary dose profile taken from the transverse slice is 
shown for each plan evaluated.   
 
4.3.2.1 6 MV IMRT abdomen patient plan 
In Figure 4.1, the DVHs from the TPS and DPM calculations of a 6 MV IMRT 
abdomen patient case are shown for the PTV and the ipsilateral kidney.  In general, The TPS 
calculation was similar to the DPM calculation, but tended to overestimate the dose similar to 
what was observed in Table 21.  At the dose volume of 90% (D90) for the PTV, the TPS 
calculation reported a dose that was 2.4% greater than the DPM calculation.  At D50 for the 
kidney, the TPS calculation reported a dose that was 3.4% greater than the DPM calculation. 
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Figure 4.1 DVH of the 6 MV IMRT abdomen patient plan for the PTV and the left (Lt) kidney. 
 
 
Figure 4.2 shows the gamma map of the axial CT image in the center of the PTV for 
the abdomen patient case between the TPS and DPM calculations.  Disagreement occurred in 
some penumbra regions.  The dose profile in Figure 4.3 showed the discrepancy in the dose 
calculations was random in the flat dose region. 
 
Figure 4.2 Gamma map (5%, 3mm) of the 6 MV IMRT abdomen patient plan and associated 
axial CT image with DPM calculated dose distribution.  The black arrow shows the dose line 
profile in the CT image for Figure 4.3. 
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Figure 4.3 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.2. 
 
4.3.2.2 6 MV SBRT lung patient plan 
In Figure 4.4, the DVHs from the TPS and DPM calculations of a 6 MV SBRT lung 
patient case are shown for the GTV, PTV, ipsilateral lung, and the heart.  The DVH 
comparisons of the GTV, lung, and heart were nearly the same.  However, at D90 for the PTV, 
the TPS calculation reported a dose that was 2.6% less than the DPM calculation.  This was 
consistent with the SBRT thorax phantom results shown below in Figure 4.16 and Figure 4.25. 
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Figure 4.4 DVH of the 6 MV SBRT lung patient plan for the GTV, PTV, left (lt) kidney lung, 
and cord. 
 
Figure 4.5 shows the gamma map of the axial CT image in the center of the PTV for 
the lung patient case between the TPS and DPM calculations.  Disagreement occurred in some 
penumbra regions and at the skin surface.  There was small disagreement in the low density 
lung region adjacent to the tumor which the dose profile in Figure 4.6 showed the DPM 
calculation predicted a wider penumbra. 
 
 
Figure 4.5 Gamma map (5%, 3mm) of the 6 MV SBRT lung patient plan and associated axial 
CT image with DPM calculated dose distribution.  The black arrow shows the dose line profile 
in the CT image for Figure 4.6. 
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Figure 4.6 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.5. 
 
4.3.2.3 10 MV IMRT prostate patient plan 
In Figure 4.7, the DVHs from the TPS and DPM calculations of a 10 MV IMRT 
prostate patient case are shown for the PTV, the anus-rectum, and the right femoral head.  The 
DVH comparisons were nearly the same.  However, the maximum dose for the DPM 
calculation was 2.7% greater than for the TPS calculation.  The dose difference to the PTV at 
D5 was 1.1%. 
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Figure 4.7 DVH of the 10 MV IMRT prostate patient plan for the PTV, anus-rectum, and the 
right (R) femoral head. 
 
Figure 4.8 shows the gamma map of the axial CT image in the center of the PTV for 
the prostate patient case between the TPS and DPM calculations.  Disagreement occurred in 
some penumbra regions and at the heterogeneous interfaces, but within the 5%/3 mm criterion.  
Otherwise, the disagreement occurred in the build-up region at the skin surface. The dose 
profile in Figure 4.9 showed the DPM calculation predicted sharper dose gradients at the 
bone/tissue interfaces as noted by the change in the CT value at this interface and about 2% less 
dose to the anus-rectum critical structure than the TPS calculation. 
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Figure 4.8 Gamma map (5%, 3mm) of the 10 MV IMRT prostate patient plan and associated 
axial CT image with DPM calculated dose distribution.  The black arrow shows the dose line 
profile in the CT image for Figure 4.9. 
 
Figure 4.9  Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.8. 
 
4.3.2.4 10 MV IMRT lung patient plan 
In Figure 4.10, the DVHs from the TPS and DPM calculations of a 10 MV IMRT lung 
patient case are shown for the PTV, carina, esophagus, and lungs.  In general, the TPS 
calculation tended to estimate the dose higher than the DPM calculation.  However, at D95 the 
DPM calculation was 3.0% higher and at D90 they were negligibly different.  The largest 
difference in the DVH comparison of the PTV was between at D30 and D80, and ranged from 
1.1% to 1.3%.  The D30 to D80 dose difference for the carina ranged from 3.6% to 7.0%.  For the 
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esophagus, the largest dose differences ranged from 7.0% to 9.8% for the dose volumes 
between D10 and D40.  The dose to the lungs was consistently the same throughout the lung 
volume. 
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Figure 4.10 DVH of the 10 MV IMRT lung patient plan for the PTV, carina, esophagus, and 
the lungs. 
 
 
Figure 4.11 shows the gamma map of the axial CT image in the center of the PTV for 
the lung patient case between the TPS and DPM calculations.  Similar to the results of all of the 
treatment plans, disagreement occurred at the skin surface as well in the beam penumbra 
regions.  The shape of the tumor was irregular so that a small volume of lung tissue was nearly 
surrounded by the tumor.  In this region, differences between the two calculations existed.  The 
dose profile in Figure 4.12 showed that only the DPM calculation predicted the build-down in 
dose within the small volume of lung that was circumscribed by the tumor.  The CT values 
reported this small region to be that of air and accordingly, the Monte Carlo code used the 
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stopping power values of dry air in computing the dose.  This would explain the large 
difference in this region.    
 
Figure 4.11 Gamma map (5%, 3mm) of the 10 MV IMRT lung patient plan and associated axial 
CT image with DPM calculated dose distribution.  The black arrow shows the dose line profile 
in the CT image for Figure 4.12. 
 
Figure 4.12 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.11. 
 
 
4.3.2.5 6 MV IMRT head and neck phantom plan 
In Figure 4.13, the DVHs from the TPS and DPM calculations of the 6 MV IMRT head 
and neck phantom benchmark are shown for the primary PTV, secondary PTV, and spinal cord 
critical structure (CS).  Large differences were noted between the two calculations.  For the 
primary target, the dose difference ranged from 4.8% at D50 to 6.7% at D95.  For the secondary 
(c
G
y
)
(cm)
(c
G
y
)
  137 
target, the dose difference ranged from 3.8% at D50 to 4.3% at D95.  The dose to the CS which 
was in close proximity to the primary target and in a dose gradient region was nearly the same 
for both calculations until approximately D50.  From D20 to D50 the TPS calculation 
overestimated the dose by about 18% in the critical structure. 
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Figure 4.13 DVH of the 6 MV IMRT head and neck phantom plan for the primary, secondary, 
and the cord (CS). 
 
 
Figure 4.14 shows the gamma map of the axial CT image in the center of the PTV for 
the head and neck phantom plan between the TPS and DPM calculations.  The gamma map 
showed disagreement within the polystyrene insert which included the solid water targets and 
the acrylic critical structure (refer to Figure 2.4 (a)) as well as the build-up region of the 
phantom surface.  The disagreement within the insert was beyond the 5%/3 mm criterion in the 
beam penumbra regions and in the primary target adjacent to the critical structure.  This was 
expected based on the IMRT quality assurance results that were detailed in Section 4.3.1 by 
studying point dose information in the PTV.  Table 21 and Table 22 showed the ratio between 
the TPS calculation and the DPM calculation in the center of the primary target was 1.049 
  138 
(mean primary target ratio was 1.043).  The dose profile in Figure 4.15 showed that the TPS 
calculation overestimated the dose in the plan across the primary and secondary targets in the 
range of 2% to 6%. 
 
 
Figure 4.14 Gamma map (5%, 3mm) of the 6 MV IMRT head and neck phantom plan and 
associated axial CT image with DPM calculated dose distribution.  The black arrow shows the 
dose line profile in the CT image for Figure 4.15. 
 
 
Figure 4.15 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.14. 
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4.3.2.6 6 MV SBRT lung phantom plan 
In Figure 4.16, the DVHs from the TPS and DPM calculations of the 6 MV SBRT lung 
phantom benchmark are shown for the target, PTV, ipsilateral lung, and heart.  While the target, 
lung, and heart DVHs between the two calculations were nearly identical, the TPS 
underestimated the dose in the PTV.  The dose differences ranged from 2.6% to 3.8% for the 
D70 to D95 portions of the PTV, respectively.  The behavior of the DVH for the PTV was the 
same for the SBRT patient case presented in Figure 4.4 above.  Since the delivery was static 
using 9 coplanar beams equally spaced and conformed to simple shaped target, the difference 
can be attributed to a wider dose penumbra for the DPM calculation. 
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Figure 4.16 DVH of the 6 MV SBRT lung phantom plan for the target, PTV, left (LT) lung 
(net), and the heart. 
 
 
Figure 4.17 shows the gamma map of the axial CT image in the center of the PTV for 
the lung phantom plan between the TPS and DPM calculations.  Disagreement within the 5%/3 
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mm criteria occurred in some penumbra regions and at the skin surface.  The dose profile in 
Figure 4.18 showed the DPM calculation predicted a slightly wider penumbra. 
 
 
 
 
Figure 4.17 Gamma map (5%, 3mm) of the 6 MV SBRT lung phantom plan and associated 
axial CT image with DPM calculated dose distribution.  The black arrow shows the dose line 
profile in the CT image for Figure 4.18. 
 
 
Figure 4.18 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.17. 
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4.3.2.7 6 MV IMRT lung phantom plan 
In Figure 4.19, the DVHs from the TPS and DPM calculations of the 6 MV IMRT lung 
phantom benchmark are shown for the GTV, PTV, ipsilateral lung, and heart.  For this plan, the 
TPS calculation tended to overestimate the dose to the target relative to the DPM calculation.  
Dose differences for the GTV were less than 2.4% and for the PTV less than 1.4%.  Dose 
predictions for the critical structures were similar. 
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Figure 4.19 DVH of the 6 MV IMRT lung phantom plan for the GTV, PTV, left (LT) lung, and 
the heart. 
 
 
Figure 4.20 shows the gamma map of the axial CT image in the center of the PTV for 
the lung phantom plan between the TPS and DPM calculations.  Disagreement beyond the 
5%/3 mm criteria occurred in some penumbra regions and at the skin surface.  The dose profile 
in Figure 4.21 showed the DPM calculation predicted a slightly narrower penumbra in the low 
dose lung region.  The TPS calculation for the IMRT lung plan did not show the same 
penumbra effect relative to the DPM calculation as was presented in the static SBRT lung plans 
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(4.3.2.2 and 4.3.2.6).  This may have been an indication that the modulated IMRT treatment 
plan minimized inaccuracies in the TPS MLC model.  
 
 
Figure 4.20 Gamma map (5%, 3mm) of the 6 MV IMRT lung phantom plan and associated 
axial CT image with DPM calculated dose distribution.  The black arrow shows the dose line 
profile in the CT image for Figure 4.21. 
 
 
Figure 4.21 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.20. 
 
 
4.3.2.8 10 MV IMRT head and neck phantom plan 
In Figure 4.22, the DVHs from the TPS and DPM calculations of the 10 MV IMRT 
head and neck phantom benchmark are shown for the primary PTV, secondary PTV, and spinal 
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cord critical structure (CS).  Similar to the 6 MV IMRT head and neck phantom DVH results, 
large differences were noted between the two calculations.  For the primary target, the dose 
difference ranged from 2.0% at D50 to 5.5% at D95.  For the secondary target, the dose 
difference ranged from 3.4% at D50 to 5.8% at D95.  The dose to the CS was nearly the same for 
both calculations until approximately D40.  From D10 to D30 the TPS calculation overestimated 
the dose by about 25% in the critical structure, which was in a high dose gradient region in 
close proximity to the primary target. 
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Figure 4.22 DVH of the 10 MV IMRT head and neck phantom plan for the primary (PTV-66), 
secondary (PTV-54), and the cord (CS). 
 
 
Figure 4.23 shows the gamma map of the axial CT image in the center of the PTV for 
the head and neck phantom plan between the TPS and DPM calculations.  The gamma map 
showed disagreement within the polystyrene insert which included the solid water targets and 
the acrylic critical structure (refer to Figure 2.4 (a)) as well as the build-up region of the 
phantom surface.  Disagreement was within the 5%/3 mm criterion in the beam penumbra 
regions, except in the adjacent region between the primary target and critical structure where 
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the disagreement exceeded the criterion.  Recall, Table 21 and Table 22 showed the ratio 
between the TPS calculation.  Disagreement was also noted at the skin surface as this was a 
common result regardless of the plan evaluated.  The dose profile in Figure 4.24 showed that 
the TPS calculation overestimated the dose and did not predict the small dose gradients that 
existed in both targets. 
 
 
 
Figure 4.23 Gamma map (5%, 3mm) of the 10 MV IMRT head and neck phantom plan and 
associated axial CT image with DPM calculated dose distribution.  The black arrow shows the 
dose line profile in the CT image for Figure 4.24. 
 
 
Figure 4.24 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.23. 
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4.3.2.9 10 MV SBRT lung phantom plan 
In Figure 4.25, the DVHs from the TPS and DPM calculations of the 10 MV SBRT 
lung phantom benchmark are shown for the target, PTV, ipsilateral lung, and heart.  While the 
target, lung, and heart DVHs between the two calculations were nearly identical, the TPS 
underestimated the dose in the PTV.  The dose differences ranged from 3.7% to 6.8% for the 
D70 to D95 portions of the PTV, respectively.  The DVH for the PTV showed a similar pattern to 
the 6 MV SBRT patient case presented in Figure 4.4 above.  Since the delivery was static using 
9 coplanar beams equally spaced and conformed to simple shaped target, the difference can be 
attributed to a wider dose penumbra for the DPM calculation. 
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Figure 4.25 DVH of the 10 MV SBRT lung phantom plan for the target, PTV, left (LT) lung 
(net), and the heart. 
 
 
Figure 4.26 shows the gamma map of the axial CT image in the center of the PTV for 
the lung phantom plan between the TPS and DPM calculations.  Disagreement within the 5%/3 
mm criteria occurred in some penumbra regions.  The dose profile in Figure 4.27 showed the 
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DPM calculation predicted a slightly wider penumbra similar to the results of the 6MV SBRT 
lung phantom and patient plans. 
 
 
 
Figure 4.26 Gamma map (5%, 3mm) of the 10 MV SBRT lung phantom plan and associated 
axial CT image with DPM calculated dose distribution.  The black arrow shows the dose line 
profile in the CT image for Figure 4.27. 
 
 
Figure 4.27 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.26. 
 
 
In Figure 4.28, the DVHs from the TPS and DPM calculations of the 10 MV IMRT 
lung phantom benchmark are shown for the target, PTV, ipsilateral lung, and heart.  For this 
plan, the TPS calculation tended to overestimate the dose to the target by less than 1.7% 
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relative to the DPM calculation.  However, the TPS calculation underestimated the dose in the 
PTV penumbra region by up to 2.7%.  The DVH dose predictions for the critical structures for 
both dose calculations were similar. 
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Figure 4.28 DVH of the 10 MV IMRT lung phantom plan for the target, PTV, left (LT) lung 
(net), and the heart 
 
 
Figure 4.29 shows the gamma map of the axial CT image in the center of the PTV for 
the lung phantom plan between the TPS and DPM calculations.  Some disagreement also 
occurred in the lung region adjacent to the target heterogeneity boundary.  This effect may be 
attributed to the superior physics modeling inherent in the Monte Carlo code.  The effect was 
not observed in the 6 MV SBRT and 6 MV IMRT phantom plans, but was noted in the lung 
patient plans and to a lesser extent in the 10 MV SBRT lung phantom plan.  The dose profile in 
Figure 4.30 showed the DPM calculation predicted a wider penumbra and a high dose at the 
target/lung interface than the TPS calculation.  The higher dose at the interface was observed in 
the measurement of the lateral dose profile (Figure 3.29). 
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Figure 4.29 Gamma map (5%, 3mm) of the 10 MV IMRT lung phantom plan and associated 
axial CT image with DPM calculated dose distribution.  The black arrow shows the dose line 
profile in the CT image for Figure 4.30. 
 
 
 
 
Figure 4.30 Dose (cGy) line profile comparing TPS and DPM calculations.  Location of profile 
is shown in the CT image of Figure 4.29. 
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Chapter 5 Summary 
 
5.1 CHAPTER 2 AND CHAPTER 3 SUMMARY FOR VARIAN MACHINE 
MODELS 
The source model was developed for the Varian 6 MV (Chapter 2) and 10 MV 
(Chapter 3) linear accelerators.  The models were validated against basic beam measurements.  
Percent depth dose curves and lateral beam profiles were calculated and compared to 
measurements for field sizes of 4 cm x 4 cm to 40 cm x 40 cm in water.   The DPM Monte 
Carlo calculations agreed well with measurements tested to criteria of 2% of the maximum dose 
along the central axis and 2 mm distance to agreement.  At least 95% of the data tested met the 
criteria.  Additional testing compared local differences between the calculation and 
measurement.  For the 6 MV and 10 MV source models, the average local percent difference 
along the central axis was no more than 2.0% and was less than 1.5% for field sizes below 20 
cm x 20 cm.  The average local percent differences of the off-axis doses (greater than or equal 
to 80% of the central axis dose) was no more than 1.3% for the field sizes tested. 
The validated source model was benchmarked against a variety of treatment techniques 
using anthropomorphic phantoms.  Point dose, dose profiles, and 2-D dose distributions were 
used to compare the DPM Monte Carlo calculation to TLD and radiochromic film 
measurements.  The 2-D dose distributions from the calculation and measurement were tested 
to criteria of 3% of the target center dose and 2 mm distance to agreement.  At least 85% of the 
data tested met the criteria.   
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5.2 CHAPTER 4 SUMMARY, PATIENT PLANS 
The validated source model with the DPM Monte Carlo code was applied to patient 
cases to establish a baseline of what might be expected from a retrospective calculation study as 
part of the clinical trial outcomes analysis.  To perform this study, a commercial treatment 
planning system’s (TPSs) dose calculation that was commissioned and used separately by two 
institutions was benchmarked against the DPM calculation.  In a parallel effort, a proof of 
principle study was performed in a similar manner to the patient cases, but was performed on 
the same anthropomorphic phantom plans used in the benchmarking of the source model with 
DPM calculation presented in Chapter 2 and Chapter 3.  In this way, the results between the 
DPM calculation and the TPS calculation were more interpretable since measurements were 
made.   
In general, the TPS calculation and DPM calculation performed similarly.  The mean 
dose to the GTV for the patient and phantoms cases were within 2% of one another, except for 
the 6 MV IMRT head and neck phantom plan which was nearly 5%.  The IMRT QA for the 
head and neck phantom plan revealed consistency from the DPM calculation, however a 
discrepancy of about 3% existed between the plan and the QA TPS calculations.  The results 
from this plan reinforced the superior physics inherent with the Monte Carlo code and 
suggested there are plans that the TPS calculation is not capable of providing accurate dose 
distribution predictions.   
Although typically within the criteria of 5%/3 mm, the beam penumbra regions had the 
greatest differences between the TPS and DPM calculated doses.  Dose changes at the 
heterogeneous boundaries were more prominent with the DPM calculation.  The TPS 
calculation reported the dose in these transitions more smoothly.  The Monte Carlo code was 
able to apply the material properties and associated material cross section data and therefore 
predicts the dose changes at the interfaces more accurately.  In low density regions such as 
lung, the DPM calculation predicted a slightly wider penumbra than the TPS calculation.  
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Differences in the dose reported at the skin surface between the two calculations were common.  
Possible causes of this could be due to modeling of the build-up region at the surface and how 
the skin surface is defined within the source model for the DPM calculation. 
5.3 EVALUATION OF THE HYPOTHESIS 
The hypothesis of this study was that a quality assurance tool based on the Monte Carlo 
Dose Planning Method (DPM) and coupled to a measurement-based source model could be 
developed to predict dose within 3%/2mm of measurement for IMRT and stereotactic 
treatments planned on the Varian linear accelerator at the photon energies of 6 MV and 10 MV. 
To evaluate the hypothesis, the source model was first developed and validated for both 
energies with sufficient accuracy.  This was accomplished in Specific Aim 1 where the model 
was commissioned by the standard set of basic beam data and performed to a criteria level 
within 2% or 2 mm for at least 95% of the data tested.  The development and validation of the 
source model was detailed in Chapter 2 for the Varian 6 MV photon beam and in Chapter 3 for 
the 10 MV Varian photon beam. 
The hypothesis was evaluated by benchmarking testing using the RPC 
anthropomorphic phantoms.  The benchmark test plan was designed to increase the level of 
difficulty for the calculation based on the treatment technique and heterogeneity of the medium.  
The head and neck phantom was used to test the homogeneous condition with IMRT.  The 
thorax phantom was used to test the low-density heterogeneous condition with SBRT and 
IMRT.  Specific Aim 2 described the condition required to test the hypothesis.  The 
requirement was that at least 85% of the data tested had to meet the stated criteria in order to 
prove the hypothesis true.  As expected, the most difficult technique and treatment in terms of 
dose prediction was the IMRT lung plans where the minimum average percent of the data 
tested meeting the criteria was 85%.   The IMRT treatment of the homogeneous medium and 
the SBRT treatment of the low-density heterogeneous medium yielded a range of the data 
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meeting criteria between 90% and 98%.  The benchmark testing results proved that the 
hypothesis was true. 
5.4 GENERAL CONCLUSIONS 
A custom-developed method for dose recalculation of patient plans entered into clinical 
trials was found to be accurate under a variety of conditions.  The measurement-driven source 
model with analytical function parameters derived from a standard set of basic beam 
measurement data exceeded the objectives specified for agreement between the calculation and 
measurement for the common range of square fields at energies of 6 MV and 10 MV.  The 
validated models also met or exceeded the objectives specified for agreement between the 
calculation and measurement for a variety of benchmark conditions using the RPC 
anthropomorphic phantoms and the common SBRT and IMRT treatment techniques.  
Confirmation of these results was demonstrated with patient cases where a commercial 
treatment planning system’s (TPSs) dose calculation algorithm was benchmarked against the 
DPM method.  The DPM method generated answers similar to the TPS system for IMRT and 
SBRT treatment plans.  Differences were consistent with the superior physics modeling 
inherent in the Monte Carlo code.  As a result, we believe the method will be useful for 
recalculating dose distributions for patients entered into clinical trials. 
 
5.5 FUTURE WORK 
This project provided the proof of principle that an accurate independent dose 
calculation tool could be developed for use in the recalculation of patient plans entered into 
clinical trials.  Currently, the custom-developed method is limited to the source models 
developed for the Varian 6 MV and 10 MV photon beams.  While the Varian linear accelerators 
(linacs) comprise of a large percentage of the linacs listed by institutions participating in 
clinical trials (according to the RPC database, 93% of over 730 institutions have Varian linacs), 
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additional work is needed to develop source models for the Elekta and Siemens linacs. Equally 
important is the need to develop models for the 18 MV photon beams, as it is common to use 
this energy alone or along with other energies for certain treatments.  Another helpful area for 
improvement lies in the speed of the calculation.  It is estimated that the calculation time is 
more than 20 times slower than the typical commercially available dose calculation algorithm.  
While some graphical user interfaces currently exist (CERR and the rpcfilm tool), the actual 
dose calculation is executed using UNIX commands.  Therefore, an effort to bring the dose 
calculation within the CERR platform would improve the ease of use.  Finally, the approach to 
compensate for the assumption that the primary source is a point source by offsetting the MLC 
leaves by a fixed amount based on the source diameter could be improved.  A better approach 
would be to modify the primary source and change it from a point source to a small Gaussian 
distributed source. 
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Chapter 6 APPENDIX 
 
 
6.1 VARIAN 6 MV: PERCENT DEPTH DOSE AND DOSE PROFILES 
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Figure 6.1 Calculated and measured percent depth dose curves at 6 MV from a 4 cm by 4 cm 
field. 
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Figure 6.2 Calculated and measured dose profiles at 6 MV from a 4 cm by 4 cm field at depths 
of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.3 Calculated and measured percent depth dose curves at 6 MV from a 5 cm by 5 cm 
field. 
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Figure 6.4 Calculated and measured dose profiles at 6 MV from a 5 cm by 5 cm field at depths 
of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.5 Calculated and measured percent depth dose curves at 6 MV from a 6 cm by 6 cm 
field. 
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Figure 6.6 Calculated and measured dose profiles at 6 MV from a 6 cm by 6 cm field at depths 
of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.7 Calculated and measured percent depth dose curves at 6 MV from a 8 cm by 8 cm 
field. 
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Figure 6.8 Calculated and measured dose profiles at 6 MV from a 8 cm by 8 cm field at depths 
of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.9 Calculated and measured percent depth dose curves at 6 MV from a 10 cm by 10 cm 
field. 
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Figure 6.10 Calculated and measured dose profiles at 6 MV from a 10 cm by 10 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.11 Calculated and measured percent depth dose curves at 6 MV from a 15 cm by 15 
cm field. 
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Figure 6.12 Calculated and measured dose profiles at 6 MV from a 15 cm by 15 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.13 Calculated and measured percent depth dose curves at 6 MV from a 20 cm by 20 
cm field. 
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Figure 6.14 Calculated and measured dose profiles at 6 MV from a 20 cm by 20 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.15 Calculated and measured percent depth dose curves at 6 MV from a 25 cm by 25 
cm field. 
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Figure 6.16 Calculated and measured dose profiles at 6 MV from a 25 cm by 25 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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Figure 6.17 Calculated and measured percent depth dose curves at 6 MV from a 40 cm by 40 
cm field. 
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Figure 6.18 Calculated and measured dose profiles at 6 MV from a 40 cm by 40 cm field at 
depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm. 
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6.2 VARIAN 6 MV: GAMMA MAPS AND DOSE PROFILES 
6.2.1 Varian 6 MV: Delivery for the IMRT head and neck plan 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 83% pass; scale 1mm = 
0.79 mm 
e) Axial: 5%/3 mm, 98% pass; scale 1mm = 
0.79 mm 
  
f) Sagittal: 3%/2 mm, 97% pass; scale 1 mm = 
1.09 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 1.09 mm 
Figure 6.19 Varian 6 MV: IMRT H&N delivery single irradiation (number 1): Gamma maps and 
dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 93% pass; scale 1mm = 
0.79 mm 
e) Axial: 5%/3 mm, 99% pass; scale 1mm = 
0.79 mm 
  
f) Sagittal: 3%/2 mm, 95% pass; scale 1 mm = 
1.09 mm 
g) Sagittal: 5%/3 mm, 99% pass; scale 1 mm = 
1.09 mm 
Figure 6.20 Varian 6 MV: IMRT H&N delivery single irradiation (number 2): Gamma maps 
and dose profiles. 
 
 
  166 
   
a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 80% pass; scale 1mm = 
0.79 mm 
e) Axial: 5%/3 mm, 97% pass; scale 1mm = 
0.79 mm 
  
f) Sagittal: 3%/2 mm, 91% pass; scale 1 mm = 
1.09 mm 
g) Sagittal: 5%/3 mm, 99% pass; scale 1 mm = 
1.09 mm 
Figure 6.21 Varian 6 MV: IMRT H&N delivery single irradiation (number 3): Gamma maps 
and dose profiles. 
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6.2.2 Varian 6 MV: Delivery for the SBRT lung plan 
   
a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 82% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 95% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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h) Coronal: 3%/2 mm, 93% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 99% pass; scale 1 mm = 
0.65 mm 
Figure 6.22 Varian 6 MV: SBRT lung delivery single irradiation (number 1): Gamma maps and 
dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 91% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 96% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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h) Coronal: 3%/2 mm, 94% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 99% pass; scale 1 mm = 
0.65 mm 
Figure 6.23 Varian 6 MV: SBRT lung delivery single irradiation (number 2): Gamma maps and 
dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 95% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 97% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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h) Coronal: 3%/2 mm, 93% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
Figure 6.24 Varian 6 MV: SBRT lung delivery single irradiation (number 3): Gamma maps and 
dose profiles. 
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6.2.3 Varian 6 MV: Delivery for the IMRT lung plan 
   
a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 88% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 99% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 87% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 95% pass; scale 1 mm = 
0.65 mm 
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h) Coronal: 3%/2 mm, 82% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 94% pass; scale 1 mm = 
0.65 mm 
Figure 6.25 Varian 6 MV: IMRT lung delivery single irradiation (number 1): Gamma maps and 
dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 92% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 99% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 92% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 99% pass; scale 1 mm = 
0.65 mm 
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h) Coronal: 3%/2 mm, 86% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 96% pass; scale 1 mm = 
0.65 mm 
Figure 6.26 Varian 6 MV: IMRT lung delivery single irradiation (number 2): Gamma maps and 
dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 89% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 98% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 87% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 96% pass; scale 1 mm = 
0.65 mm 
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h) Coronal: 3%/2 mm, 85% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 97% pass; scale 1 mm = 
0.65 mm 
Figure 6.27 Varian 6 MV: IMRT lung delivery single irradiation (number 3): Gamma maps and 
dose profiles. 
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6.3 VARIAN 10 MV: GAMMA MAPS AND DOSE PROFILES 
6.3.1 Varian 10 MV: Delivery for the IMRT head and neck plan 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 97% pass; scale 1mm = 
0.79 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.79 mm 
  
f) Sagittal: 3%/2 mm, 92% pass; scale 1 mm = 
1.09 mm 
g) Sagittal: 5%/3 mm, 99% pass; scale 1 mm = 
1.09 mm 
Figure 6.28 Varian 10 MV: IMRT H&N delivery single irradiation (number 1): Gamma maps 
and dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 93% pass; scale 1mm = 
0.79 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.79 mm 
  
f) Sagittal: 3%/2 mm, 90% pass; scale 1 mm = 
1.09 mm 
g) Sagittal: 5%/3 mm, 98% pass; scale 1 mm = 
1.09 mm 
Figure 6.29 Varian 10 MV: IMRT H&N delivery single irradiation (number 2): Gamma maps 
and dose profiles. 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 99% pass; scale 1mm = 
0.79 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.79 mm 
  
f) Sagittal: 3%/2 mm, 93% pass; scale 1 mm = 
1.09 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 1.09 mm 
Figure 6.30 Varian 10 MV: IMRT H&N delivery single irradiation (number 3): Gamma maps 
and dose profiles. 
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6.3.2 Varian 10 MV: Delivery for the SBRT lung plan 
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a) Lateral profile b) Anterior to posterior profile c) Superior to inferior profile 
  
d) Axial: 3%/2 mm, 98% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 97% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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h) Coronal: 3%/2 mm, 98% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
Figure 6.31 Varian 10 MV: SBRT lung delivery single irradiation (number 1): Gamma maps 
and dose profiles. 
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d) Axial: 3%/2 mm, 96% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 95% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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h) Coronal: 3%/2 mm, 91% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
Figure 6.32 Varian 10 MV: SBRT lung delivery single irradiation (number 2): Gamma maps 
and dose profiles. 
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d) Axial: 3%/2 mm, 98% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 100% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 97% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
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h) Coronal: 3%/2 mm, 98% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 100% pass; scale 1 mm 
= 0.65 mm 
Figure 6.33 Varian 10 MV: SBRT lung delivery single irradiation (number 3): Gamma maps 
and dose profiles. 
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6.3.3 Varian 10 MV: Delivery for the IMRT lung plan 
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d) Axial: 3%/2 mm, 88% pass; scale 1mm = 
0.82 mm 
e) Axial: 5%/3 mm, 97% pass; scale 1mm = 
0.82 mm 
  
f) Sagittal: 3%/2 mm, 84% pass; scale 1 mm = 
0.65 mm 
g) Sagittal: 5%/3 mm, 95% pass; scale 1 mm = 
0.65 mm 
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h) Coronal: 3%/2 mm, 86% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 98% pass; scale 1 mm = 
0.65 mm 
Figure 6.34 Varian 10 MV: IMRT lung delivery single irradiation (number 1): Gamma maps 
and dose profiles. 
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h) Coronal: 3%/2 mm, 83% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 98% pass; scale 1 mm = 
0.65 mm 
Figure 6.35 Varian 10 MV: IMRT lung delivery single irradiation (number 2): Gamma maps 
and dose profiles. 
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h) Coronal: 3%/2 mm, 80% pass; scale 1 mm = 
0.65 mm 
i) Coronal: 5%/3 mm, 96% pass; scale 1 mm = 
0.65 mm 
Figure 6.36 Varian 10 MV: IMRT lung delivery single irradiation (number 3): Gamma maps 
and dose profiles. 
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